[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1903
1. Woo JS, Kim JM, Lee SH, Chae SW, Hwang SJ, Lee HM: Clinical analysis of extranodal non-Hodgkin's lymphoma in the sinonasal tract. Eur Arch Otorhinolaryngol; 2004 Apr;261(4):197-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical analysis of extranodal non-Hodgkin's lymphoma in the sinonasal tract.
  • We investigated the clinical analysis of non-Hodgkin's lymphoma (NHL) of the sinonasal tract, including the survival rate and treatment outcome.
  • Fifty patients who had previously received a diagnosis of extranodal NHL of the sinonasal cavity from May 1992 to April 2001 were included.
  • Of 50 patients, 49 were classified as having extranodal NK/T cell lymphoma and only one patient as having diffuse large B cell (DLBC) lymphoma according to the new WHO classification.
  • Even though higher mortality rates were observed in patients receiving chemotherapy alone than in those receiving chemotherapy and radiation therapy in the advanced stage, the combination treatment of chemotherapy and radiation therapy failed to demonstrate a significantly higher survival rate.
  • [MeSH-major] Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / therapy. Paranasal Sinus Neoplasms / mortality. Paranasal Sinus Neoplasms / therapy. Paranasal Sinuses / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Biopsy, Needle. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Probability. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1987 Jun;11(6):418-29 [3496014.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Ann Oncol. 2001 Mar;12(3):349-52 [11332147.001]
  • [Cites] Hum Pathol. 1997 Jul;28(7):834-9 [9224753.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S46-55 [9894469.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):153-60 [10924985.001]
  • [Cites] Int J Cancer. 1984 Aug 15;34(2):143-8 [6381328.001]
  • [Cites] Acta Oncol. 1997;36(3):307-11 [9208902.001]
  • [Cites] Auris Nasus Larynx. 2001 Jan;28(1):55-60 [11137364.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):161-8 [10924986.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Yonsei Med J. 2002 Apr;43(2):175-82 [11971211.001]
  • [Cites] Hematol Oncol. 2001 Dec;19(4):129-50 [11754390.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]
  • [Cites] Cancer. 1990 Nov 15;66(10):2205-9 [2224776.001]
  • [Cites] Radiology. 1997 Aug;204(2):467-70 [9240537.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1989;414(5):399-405 [2499096.001]
  • [Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]
  • [Cites] Hum Pathol. 1987 Dec;18(12):1257-62 [3500108.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):477-88 [9241082.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):643-51 [11849785.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1228-33 [11728681.001]
  • [Cites] Blood. 1993 May 15;81(10):2688-95 [8387835.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):806-12 [9708949.001]
  • [Cites] Laryngoscope. 2000 Sep;110(9):1489-92 [10983948.001]
  • [Cites] Hum Pathol. 1994 Jul;25(7):659-65 [8026825.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1994 Nov;103(11):911-4 [7979008.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):821-9 [9217183.001]
  • [Cites] Histopathology. 1994 Dec;25(6):517-36 [7698729.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):70-7 [9440725.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1990 Jan;116(1):69-73 [2294944.001]
  • (PMID = 12898138.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Rawls RA, Vega KJ, Trotman BW: Small Bowel Lymphoma. Curr Treat Options Gastroenterol; 2003 Feb;6(1):27-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small Bowel Lymphoma.
  • Treatment of small bowel lymphoma requires the expertise of medical and surgical subspecialists.
  • The two most important factors that determine the optimal treatment are histology and staging of small bowel lymphoma.
  • Other factors that may affect treatment include age, multiple areas of involvement, tumor size, and perforation.
  • At present, the best treatment for gastrointestinal lymphoma (stage IE disease) is limited resection of the tumor, followed by postoperative radiotherapy.
  • The cure rate is approximately 75% for stage IE patients, even for those with aggressive histologic types.
  • Chemotherapy is reserved for advanced-staged tumors.
  • In patients with regional nodal involvement or extranodal involvement confined to one side of the diaphragm (pathologic stage IIE disease), chemotherapy should be combined with radiation therapy.
  • The best chemotherapy regimen depends on the histology of the tumor.
  • For diffuse large B-cell lymphoma, the most frequently diagnosed subtype of non-Hodgkin's lymphoma (NHL), the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) is still the gold standard.
  • Clinical trials have been conducted evaluating the new monoclonal antibody rituximab, along with the CHOP regimen for primary NHL.
  • The use of rituximab in the treatment of extranodal lymphoma is still being evaluated.
  • Low-grade lymphomas have a more indolent course and do not respond as well to combination chemotherapy agents as the high-grade tumors.
  • Fludarabine alone or in combination with cyclophosphamide is effective as a first-line agent for patients with low-grade NHL.
  • It has also been used to treat relapsed or refractory low-grade NHL.
  • Some promising results have been reported using the chemoimmunotherapy agent rituximab alone or in combination with fludarabine for the treatment of low-grade NHL.
  • In patients with nodal involvement on both sides of the diaphragm or other extranodal involvement such as bone marrow or liver (pathologic stages IIIE and IVE), the disease is managed primarily with combination chemotherapy.
  • Radiation therapy is reserved for treatment of initially bulky tumor sites, treatment of residual disease following chemotherapy, or serious local problems.
  • As with stage IIE disease, the optimal chemotherapy regimen depends on the histologic subtype of NHL.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Pharm Biotechnol. 2001 Dec;2(4):279-91 [11762410.001]
  • [Cites] Blood. 2000 May 15;95(10):3052-6 [10807768.001]
  • [Cites] Am J Surg Pathol. 1993 May;17(5):429-42 [8470758.001]
  • [Cites] J Clin Gastroenterol. 2001 Oct;33(4):267-82 [11588539.001]
  • [Cites] Prog Allergy. 1986;37:259-300 [3515352.001]
  • [Cites] Am J Gastroenterol. 1994 May;89(5):699-701 [8172140.001]
  • [Cites] Semin Oncol. 1988 Apr;15(2):154-69 [3285479.001]
  • [Cites] Clin Gastroenterol. 1983 Sep;12(3):743-66 [6413104.001]
  • [Cites] Semin Oncol. 2002 Apr;29(2 Suppl 6):18-22 [12040530.001]
  • [Cites] Ann Hematol. 2001;80 Suppl 3:B63-5 [11757711.001]
  • [Cites] Ann Hematol. 2001;80 Suppl 3:B132-4 [11757697.001]
  • [Cites] Cancer. 1982 Feb 1;49(3):445-9 [6895859.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):324-37 [10375089.001]
  • [Cites] N Engl J Med. 1985 Jul 18;313(3):166-71 [4010708.001]
  • [Cites] Gastroenterology. 1982 Jan;82(1):143-52 [7053326.001]
  • [Cites] Am J Med. 1987 Mar 23;82(3 Spec No):649-54 [3030102.001]
  • [Cites] Semin Oncol. 2002 Apr;29(2 Suppl 6):11-7 [12040529.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):36-40 [28140090.001]
  • (PMID = 12521569.001).
  • [ISSN] 1092-8472
  • [Journal-full-title] Current treatment options in gastroenterology
  • [ISO-abbreviation] Curr Treat Options Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Zhao WL: Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. Leukemia; 2010 Jan;24(1):13-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways.
  • T-cell malignancies, mainly known as T-cell acute lymphoblastic leukemia (T-ALL) and T-cell non-Hodgkin's lymphoma (T-NHL), are aggressive tumors.
  • Although the clinical outcome of the patients has improved dramatically with combination chemotherapy, significant challenges remain, including understanding of the factors that contribute to the malignant behavior of these tumor cells and developing subsequently optimal targeted therapy.
  • Aberrant cell signal transduction is generally involved in tumor progression and drug resistance.
  • This review describes the pathogenetic role of multiple cellular signaling pathways in T-cell malignancies and the potential therapeutic strategies based on the modulation of these key signaling networks.
  • [MeSH-major] Lymphoma, T-Cell / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Signal Transduction / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19865108.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / NFATC Transcription Factors; 0 / NOTCH1 protein, human; 0 / NOTCH3 protein, human; 0 / Receptor, Notch1; 0 / Receptors, Notch; 0 / STAT5 Transcription Factor; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.2 / Janus Kinase 2; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Number-of-references] 116
  •  go-up   go-down


Advertisement
4. Lones MA, Perkins SL, Sposto R, Kadin ME, Kjeldsberg CR, Wilson JF, Cairo MS: Large-cell lymphoma arising in the mediastinum in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report. J Clin Oncol; 2000 Nov 15;18(22):3845-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large-cell lymphoma arising in the mediastinum in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report.
  • PURPOSE: Large-cell lymphoma (LCL) arising in the mediastinum (LCL-M) is a heterogeneous group of non-Hodgkin's lymphoma (NHL) that includes B-cell lymphomas as well as T-cell lymphomas, including anaplastic LCL.
  • LCL-M is well recognized in young adults but is less well characterized and infrequent in children and adolescents.
  • METHODS: A retrospective review of Children's Cancer Group therapeutic studies for nonlymphoblastic lymphomas (CCG-551, CCG-503, CCG-552, and CCG-5911) identified 20 patients with LCL-M, representing 7.2% of all LCLs classified by central pathology review.
  • Although a variety of chemotherapy regimens were used, response was excellent, with all 20 patients (100%) achieving a complete response.
  • One patient died of sepsis during therapy.
  • CONCLUSION: LCL-M is a heterogeneous group of NHLs that makes up approximately 7.2% of LCL in children and adolescents.
  • Response to therapy and OS in this young age group seems excellent and superior to that of disseminated LCLs but inferior to that of other localized LCL.
  • Future studies of LCL-M will evaluate short intense chemotherapy administered without radiation therapy.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Clinical Trials as Topic. Female. Humans. Male. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11078498.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 02971; United States / NCI NIH HHS / CA / CA 13539; United States / NCI NIH HHS / CA / CA 17829; etc
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


5. Harjunpää A, Taskinen M, Nykter M, Karjalainen-Lindsberg ML, Nyman H, Monni O, Hemmer S, Yli-Harja O, Hautaniemi S, Meri S, Leppä S: Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. Br J Haematol; 2006 Oct;135(1):33-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP.
  • Rituximab in combination with chemotherapy (immunochemotherapy) is one of the most effective treatments available for follicular lymphoma (FL).
  • This study aimed to determine whether differences in gene expression in FL tissue correlate with outcome in response to rituximab and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy (R-CHOP).
  • We divided 24 patients into long- [time to treatment failure (TTF) >35 months] and short-term (TTF <23 months) responders, and analysed the gene expression profiles of lymphoma tissue using oligonucleotide microarrays.
  • Among the transcripts with a high correlation between microarray and qPCR analyses, we identified EPHA1, a tyrosine kinase involved in transepithelial migration, SMAD1, a transcription factor and a mediator of bone morphogenetic protein and transforming growth factor-beta signalling, and MARCO, a scavenger receptor on macrophages.
  • We conclude that gene expression in non-malignant cells contributes to clinical outcome in R-CHOP-treated FL patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / genetics. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Gene Expression. Gene Expression Profiling / methods. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis / methods. Pilot Projects. Polymerase Chain Reaction / methods. Prednisone / administration & dosage. Receptor, EphA1 / metabolism. Rituximab. Smad Proteins / metabolism. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16925574.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Smad Proteins; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Receptor, EphA1; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


6. Pelosi E, Pregno P, Penna D, Deandreis D, Chiappella A, Limerutti G, Vitolo U, Mancini M, Bisi G, Gallo E: Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Radiol Med; 2008 Jun;113(4):578-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
  • PURPOSE: The aim of this study was to evaluate the role of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in the staging of Hodgkin's and aggressive non-Hodgkin's lymphoma (HL and NHL), comparing it with conventional diagnostic methods, i.e. contrast-enhanced CT and bone marrow biopsy.
  • MATERIALS AND METHODS: Sixty-five consecutive patients (30 HL and 35 NHL) who underwent conventional disease staging and FDG-PET/CT were included.
  • In 5/65 patients, chemotherapy treatment was modified on the basis of PET findings.
  • CONCLUSIONS: Our data confirm the high accuracy of FDG-PET/CT in staging HL and NHL.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / diagnostic imaging. Lymphoma, Non-Hodgkin / diagnostic imaging. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Sensitivity and Specificity


7. Kirsch C, Breidert M, Nagel M, Kessler U, Kittner T, Gaertner HJ, Ehninger G: [Secondary high-grade MALT lymphoma of the stomach in a 69-year-old patient with gastrocolic fistula]. Z Gastroenterol; 2001 Jan;39(1):77-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Secondary high-grade MALT lymphoma of the stomach in a 69-year-old patient with gastrocolic fistula].
  • [Transliterated title] Sekundär hoch malignes MALT-Lymphom des Magens bei einem 69-jährigen Patienten mit gastrokolischer Fistel.
  • Upper endoscopy had been performed prior by an outpatient gastroenterologist and the patient had received an eradication therapy for a Helicobacter pylori-induced gastritis.
  • Endosonography, computed tomography and an upper gastrointestinal series with water soluble media revealed a gastrocolic fistula.
  • Multiple biopsies showed a low-grade gastric MALT lymphoma.
  • The histology of the completely removed stomach revealed a high-grade Non Hodgkin Lymphoma (NHL) with parts of a low-grade NHL.
  • 3 weeks after surgery chemotherapy was started with the CHOP-regime which was well-tolerated by the patient.
  • [MeSH-major] Colonic Diseases / diagnosis. Gastric Fistula / diagnosis. Helicobacter Infections / diagnosis. Helicobacter pylori. Intestinal Fistula / diagnosis. Lymphoma, B-Cell, Marginal Zone / diagnosis. Peptic Ulcer Perforation / diagnosis. Stomach Neoplasms / diagnosis. Stomach Ulcer / diagnosis
  • [MeSH-minor] Aged. Gastrectomy. Gastric Mucosa / pathology. Gastroscopy. Humans. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / surgery. Male. Tomography, X-Ray Computed


8. Formica V, Norman AR, Cunningham D, Wotherspoon A, Oates J, Chong G: Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients. Acta Haematol; 2009;122(4):193-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients.
  • BACKGROUND: The Follicular Lymphoma International Prognostic Index (FLIPI) allows physicians to stratify patients into groups with distinct prognoses, however its ability to predict the treatment efficacy has not been fully investigated.
  • The aim of this study was to validate on this respect the FLIPI system in an independent cohort and compare it with the International Prognostic Index (IPI) used for aggressive lymphomas.
  • METHODS: Records from patients referred to our unit with a diagnosis of follicular lymphoma (FL) were retrospectively reviewed.
  • Data required for FLIPI and IPI scores were collected along with data regarding first-line chemotherapy and time to treatment failure (TTF) and overall survival (OS).
  • For patients receiving first-line chemotherapy within 6 months of diagnosis, a low FLIPI score was associated with a longer TTF (3-year TTF rates: 68.0, 33.7 and 31.0% for FLIPI-defined LR, IR and HR patients, respectively, p = 0.026).
  • A low FLIPI score was also associated with a longer TTF.
  • [MeSH-major] Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Great Britain / epidemiology. Humans. International Agencies. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Treatment Failure. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19887775.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Switzerland
  •  go-up   go-down


9. Boland A, Bagust A, Hockenhull J, Davis H, Chu P, Dickson R: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma. Health Technol Assess; 2009 Sep;13 Suppl 2:41-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
  • This paper presents a summary of the evidence review group report into the clinical effectiveness and cost-effectiveness of rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (NHL), in accordance with the licensed indication, based upon the evidence submission from Roche Products Ltd to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process.
  • The submitted clinical evidence included two randomised controlled trials [European Organisation for Research and Treatment of Cancer (EORTC) and German Low Grade Lymphoma Study Group - Fludarabine, Cyclophosphamide and Mitoxantrone and (GLSG-FCM)] comparing the clinical effects of chemotherapy with or without rituximab in the induction of remission at first or second relapse and the clinical benefits of rituximab maintenance therapy versus the NHS's current clinical practice of observation for follicular lymphoma (FL) patients.
  • Both trials showed that in patients with relapsed FL the addition of rituximab to chemotherapy induction treatment increased overall response rates.
  • Furthermore, rituximab maintenance therapy increased the median length of remission when compared with observation only.
  • Safety data from the two trials showed that while the majority of patients reported some adverse events, the number of patients withdrawing from treatment in the EORTC trial was low, with rates not being reported for the GLSG-FCM trial.
  • The manufacturer reported that maintenance therapy with rituximab was cost-effective compared with observation against commonly applied thresholds, with an incremental cost-effectiveness ratio of 7721 pounds per QALY gained.
  • The greatest clinical effectiveness is achieved by R-CHOP followed by rituximab maintenance (R-CHOP>R) and this treatment strategy had the greatest probability of being cost-effective for a QALY of approximately 18,000 pounds or greater.
  • The guidance issued by NICE as a result of the STA states that in people with relapsed stage III or IV follicular NHL, rituximab is now an option in combination with chemotherapy to induce remission or alone as maintenance therapy during remission.
  • Rituximab monotherapy is also an option for people with relapsed or refractory disease when all alternative treatment options have been exhausted.
  • [MeSH-major] Antibodies, Monoclonal / economics. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / economics. Antineoplastic Agents / therapeutic use. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Comparative Effectiveness Research. Cost-Benefit Analysis. Drug Resistance, Neoplasm. Humans. Quality-Adjusted Life Years. Randomized Controlled Trials as Topic. Recurrence. Rituximab

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19804688.001).
  • [ISSN] 2046-4924
  • [Journal-full-title] Health technology assessment (Winchester, England)
  • [ISO-abbreviation] Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 12
  •  go-up   go-down


11. Petryk M, Grossbard ML: Rituximab therapy of B-cell neoplasms. Clin Lymphoma; 2000 Dec;1(3):186-94; discussion 195-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab therapy of B-cell neoplasms.
  • The development of rituximab, an anti-CD20 monoclonal antibody, represents a revolutionary advance in the therapy of hematological malignancies.
  • Rituximab was approved in 1997 by the Food and Drug Administration for the treatment of relapsed or refractory, CD20(+), B-cell, low-grade or follicular non-Hodgkin's lymphoma (NHL).
  • Recent studies have documented activity of rituximab in other CD20-expressing hematological malignancies including mantle cell lymphoma, small lymphocytic lymphoma, aggressive NHL, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia.
  • When used in combination with cytotoxic chemotherapy, rituximab achieves response rates of 90%-95% in low-grade follicular and aggressive NHL patients.
  • Currently, rituximab is undergoing intensive investigation in several large phase II and III trials, both as a single agent and in combination with chemotherapy.
  • Clinical research will help define the ultimate role of this agent and its potential impact on survival of patients with B-cell neoplasms.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Clinical Trials as Topic. Combined Modality Therapy. Humans. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707828.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 53
  •  go-up   go-down


12. Brave M, Farrell A, Ching Lin S, Ocheltree T, Pope Miksinski S, Lee SL, Saber H, Fourie J, Tornoe C, Booth B, Yuan W, He K, Justice R, Pazdur R: FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology; 2010;78(3-4):282-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: On December 15, 2008, the US Food and Drug Administration approved plerixafor (Mozobil; Genzyme Corp.
  • ), a new small-molecule inhibitor of the CXCR4 chemokine receptor, for use in combination with granulocyte colony-stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSC) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).
  • EXPERIMENTAL DESIGN: The safety and efficacy of plerixafor were demonstrated by 2 multicenter, randomized, placebo-controlled studies in patients with NHL and MM who were eligible for autologous HSC transplantation.
  • The primary efficacy end points were the collection of > or = 5 x 10(6) CD34+ cells/kg from the peripheral blood in 4 or fewer apheresis sessions in patients with NHL or > or = 6 x 10(6) CD34+ cells/kg from the peripheral blood in 2 or fewer apheresis sessions in patients with MM.
  • RESULTS: The 2 randomized studies combined enrolled 600 patients (298 with NHL and 302 with MM).
  • Fifty-nine percent of patients with NHL who were mobilized with G-CSF and plerixafor had peripheral blood HSC collections of > or = 5 x 10(6) CD34+ cells/kg in 4 or fewer apheresis sessions, compared with 20% of patients with NHL who were mobilized with G-CSF and placebo (p < 0.001).
  • CONCLUSIONS: This report describes the Food and Drug Administration review supporting the approval of plerixafor.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization / methods. Heterocyclic Compounds / administration & dosage. Multiple Myeloma / drug therapy
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / biosynthesis. Clinical Trials as Topic. Female. Humans. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Multicenter Studies as Topic. Placebos. Product Surveillance, Postmarketing. Randomized Controlled Trials as Topic. Receptors, CXCR4 / metabolism. United States. United States Food and Drug Administration

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20530974.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / CXCR4 protein, human; 0 / Heterocyclic Compounds; 0 / Placebos; 0 / Receptors, CXCR4; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 155148-31-5 / JM 3100
  •  go-up   go-down


13. Todisco M: Low-grade non-Hodgkin lymphoma at advanced stage: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, retinoids, and melatonin. Am J Ther; 2007 Jan-Feb;14(1):113-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade non-Hodgkin lymphoma at advanced stage: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, retinoids, and melatonin.
  • Low-grade non-Hodgkin lymphomas (NHLs) at advanced stage are still incurable, and treatment may include chemotherapy with a single drug or a combination of different drugs.
  • With a combination of cyclophosphamide, somatostatin, bromocriptin, retinoids, melatonin, and adrenocorticotropic hormone, we already reported 100% of global response (50% complete response and 50% partial response) in 12 patients with low-grade NHL at advanced stage: 4 previously untreated patients and 8 with relapse of disease after single or combined chemotherapy and therapy free time >or=6 months.
  • This provided the rationale to treat a patient affected by low-grade NHL stage 4, with cyclophosphamide, somatostatin, bromocriptin, retinoids, and melatonin (adrenocorticotropic hormone was not administered for high blood pressure).
  • After this period, if he had stable or responding disease, he received an additional 3 months of treatment, and if he was stable or responding after 5 months he was treated for 3 months and more.
  • Today, 18 months after the beginning of treatment, the patient is in complete remission.
  • Treatment had very good tolerance, and the patient carried on at home doing his normal activities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MELATONIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17303979.001).
  • [ISSN] 1075-2765
  • [Journal-full-title] American journal of therapeutics
  • [ISO-abbreviation] Am J Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Retinoids; 3A64E3G5ZO / Bromocriptine; 51110-01-1 / Somatostatin; 8N3DW7272P / Cyclophosphamide; JL5DK93RCL / Melatonin
  •  go-up   go-down


14. Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG: Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother; 2006 Mar;40(3):402-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In clinical trials in patients receiving myelosuppressive chemotherapy, 10-11 days of prophylaxis with filgrastim has been found to reduce the incidence of febrile neutropenia.
  • In clinical practice, however, many patients receive shorter courses of therapy, even though the effectiveness of this regimen is unknown.
  • OBJECTIVE: To examine the relationship between duration of filgrastim prophylaxis and risk of hospitalization in patients receiving chemotherapy for non-Hodgkin's lymphoma (NHL), breast cancer, or lung cancer.
  • METHODS: Using a large, automated, US healthcare claims database, we identified all adults who received chemotherapy for NHL, breast cancer, or lung cancer between 1998 and 2002.
  • For these patients, we identified their first course of chemotherapy and each unique cycle within that course.
  • RESULTS: Mean +/- SD duration of filgrastim prophylaxis was 6.5 +/- 3.1 days across 332 cycles for 133 NHL patients, 6.1 +/- 2.9 days across 482 cycles for 205 breast cancer patients, and 4.3 +/- 3.1 days across 522 cycles for 260 lung cancer patients.
  • In multivariate analyses, risk of hospitalization for neutropenia or infection was found to decline with each additional day of filgrastim prophylaxis for patients with NHL (OR 0.81; p = 0.003), breast cancer (OR 0.77; p = 0.001), and lung cancer (OR 0.91; p = 0.084).
  • Risk reductions with each additional day of prophylaxis ranged from 15% to 19% for patients with NHL, 17% to 23% for those with breast cancer, and 8% to 9% for those with lung cancer.
  • CONCLUSIONS: Among patients with NHL, breast cancer, or lung cancer, shorter courses of filgrastim prophylaxis may increase the risk of hospitalization.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / therapeutic use. Neutropenia / chemically induced. Neutropenia / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Breast Neoplasms / blood. Breast Neoplasms / complications. Breast Neoplasms / drug therapy. Data Interpretation, Statistical. Female. Filgrastim. Hospitalization. Humans. Insurance, Health / statistics & numerical data. Lung Neoplasms / blood. Lung Neoplasms / complications. Lung Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / blood. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged. Recombinant Proteins. Retrospective Studies. Risk. Treatment Outcome. United States

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Filgrastim .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16492793.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


15. Ishii K, Urase F, Nagare Y, Kimura H, Manabe M, Yagi T, Teshima H, Hayashi K, Shibano M, Tsukaguchi M, Katsurada T, Mugitani A, Kitayama H, Nomura S: VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience. Arch Gerontol Geriatr; 2010 Sep-Oct;51(2):209-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience.
  • CHOP (cyclophosphamide, adriamycin, vincristine, and prednisolone) plus rituximab is a standard chemotherapy used to treat patients with aggressive B-cell non-Hodgkin lymphoma (B-NHL).
  • We report our clinical experience in 8 collaborative institutions to determine if the VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone, and bleomycin) combination therapy plus rituximab was effective and safe to treat elderly patients with aggressive B-NHL.
  • Complete remission rate was 90.5%, with a 100% overall response rate (RR) at the end of induction therapy; overall survival (OS) rate at 3 years was 76.4% (median follow-up 744 days), with an 82.6% 3-year progression-free survival (PFS) rate (median follow-up 744 days).
  • The most common grade 3/4 toxicities were hematologic, including neutropenia in 75.0% of the patients despite prophylactic administration of granulocyte colony-stimulating factor (G-CSF), febrile neutropenia in 30.0%, respectively.
  • There was no treatment-related mortality (TRM).
  • Rituximab not only combined with chemotherapy but also given sequentially improved survival.
  • [MeSH-major] Antibodies, Monoclonal, Murine-Derived / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Bleomycin / adverse effects. Bleomycin / therapeutic use. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Male. Mitoxantrone / adverse effects. Mitoxantrone / therapeutic use. Neutropenia / chemically induced. Prednisone / adverse effects. Prednisone / therapeutic use. Remission Induction. Rituximab. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19926148.001).
  • [ISSN] 1872-6976
  • [Journal-full-title] Archives of gerontology and geriatrics
  • [ISO-abbreviation] Arch Gerontol Geriatr
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; VNCOP-B protocol
  •  go-up   go-down


16. van Oers MH: Rituximab maintenance therapy: a step forward in follicular lymphoma. Haematologica; 2007 Jun;92(6):826-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab maintenance therapy: a step forward in follicular lymphoma.
  • Whilst recent advances in the treatment of follicular lymphoma (FL) have improved the outlook for many patients, relapses still occur and the search continues for strategies to extend the duration of remission without significantly increasing toxicity.
  • One such strategy is the use of rituximab maintenance therapy for patients responding to initial induction.
  • There is now a large body of evidence demonstrating clear benefits of rituximab maintenance versus observation following induction with either rituximab plus chemotherapy (R chemo), chemotherapy alone, or rituximab monotherapy, in both first-line and relapsed/refractory settings.
  • A very important finding is that rituximab maintenance can significantly improve overall survival in FL patients responding to induction with either R-chemo or chemotherapy alone.
  • However, the optimal dose, schedule, and duration of maintenance therapy still need to be established.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Disease Management. Humans. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550856.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 38
  •  go-up   go-down


17. Jahnke K, Thiel E, Schilling A, Herrlinger U, Weller M, Coupland SE, Krümpelmann U, Stein H, Korfel A: Low-grade primary central nervous system lymphoma in immunocompetent patients. Br J Haematol; 2005 Mar;128(5):616-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade primary central nervous system lymphoma in immunocompetent patients.
  • Primary central nervous system lymphomas (PCNSL) are usually diffuse large B-cell non-Hodgkin's lymphomas (NHL).
  • Here we characterize the clinical presentation, course and outcome of patients with low-grade PCNSL.
  • Ten patients (3%) with a median age of 59 years and a median Karnofsky performance status of 70% were identified.
  • Seven patients had B-cell and three had T-cell lymphoma.
  • Three patients underwent complete tumour resection, combined with chemotherapy in one patient and with chemotherapy plus local radiotherapy in another.
  • Four patients received chemotherapy and three received chemotherapy plus whole-brain irradiation, resulting in four complete remissions, two no-change situations and one progressive disease.
  • Patients had an overall survival (OAS) of 2-58+ months with a 2-year OAS of 67%.
  • Low-grade PCNSL may differ from classical high-grade PCNSL in its clinical features and radiological morphology.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / therapy. Magnetic Resonance Imaging. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725082.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


18. Dreyling M, Trümper L, von Schilling C, Rummel M, Holtkamp U, Waldmann A, Wehmeyer J, Freund M: Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma--role of radioimmunotherapy. Ann Hematol; 2007 Feb;86(2):81-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma--role of radioimmunotherapy.
  • Radioimmunotherapy (RIT) was approved for the treatment of relapsed or refractory CD20-positive follicular lymphoma (FL), subsequent to rituximab containing primary therapy.
  • Therefore, a consensus meeting was held in May 2005 to define the optimal setting of RIT in the therapeutic algorithm of patients with advanced stage of FL.
  • RIT is an established therapeutic option in relapsed FL.
  • First-line RIT may be applied in patients not appropriate for chemotherapy induction.
  • [MeSH-major] Algorithms. Lymphoma, Follicular / pathology. Lymphoma, Follicular / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Germany. Humans. Medical Oncology. Neoplasm Staging. Recurrence. Time Factors

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17068667.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article
  • [Publication-country] Germany
  • [Number-of-references] 41
  •  go-up   go-down


19. Büchler T, Ferra C, Virgili N, Montanya E, Grañena A: A relapsed non-Hodgkin lymphoma presenting as panhypopituitarism successfully treated by chemotherapy. J Neurooncol; 2002 Aug;59(1):35-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A relapsed non-Hodgkin lymphoma presenting as panhypopituitarism successfully treated by chemotherapy.
  • We report a case of relapsed large B-cell non-Hodgkin lymphoma (NHL) affecting the anterior pituitary.
  • The NHL relapsed after three years in complete remission.
  • After controlling the hormonal deficiencies with substitution using hydroxycortisone and levothyroxin, the patient was treated with combination chemotherapy using cyclophosphamide, vincristine, mitoxantrone, etoposide, and bleomycin (VNCOP-B regimen), achieving a complete regression of the pituitary mass and partial recovery of the endocrine function.
  • To our knowledge this is the first report of a relapsed NHL presenting by hypopituitarism.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Etoposide / therapeutic use. Hypopituitarism / etiology. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / drug therapy. Mitoxantrone / therapeutic use. Neoplasm Recurrence, Local / complications. Neoplasm Recurrence, Local / drug therapy. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Aged. Female. Humans. Magnetic Resonance Imaging. Treatment Outcome


20. Mileshkin LR, Seymour JF, Wolf MM, Gates P, Januszewicz EH, Joyce P, Prince HM: Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma; 2005 Nov;46(11):1575-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older.
  • High-dose therapy (HDT) for non-Hodgkins lymphoma (NHL) and multiple myeloma (MM) is considered a feasible option for patients aged 60 years.
  • This study compared the outcomes for all patients aged 60 years treated with HDT at the center to a matched cohort group aged <60 years.
  • Event-free (EFS) and overall survival (OS) rates were compared with a cohort group, matched by disease type, chemotherapy sensitivity, year of treatment and conditioning regimen.
  • Patients with NHL were also matched by International Prognostic Index score.
  • Median age was 65 (range 60--76) with 22 MM and 18 NHL; 50% had 1 or more co-morbidity; 35% had cardiovascular co-morbidity vs. 18% of controls (p=0.075).
  • For NHL patients there were: 8 CR (44%) and 4 PR (22%), giving an ORR of 67%, vs. 83% for controls (p=0.3).
  • Toxicities were similar with the exception of cardiac toxicity, which was significantly higher in patients aged 60 years vs. controls (50% grade 3 vs. 10%: p<0.0001).
  • HDT is feasible and effective in selected patients 60 years with MM and NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cardiovascular Diseases / chemically induced. Drug-Related Side Effects and Adverse Reactions. Lymphoma, Non-Hodgkin / complications. Multiple Myeloma / complications. Peripheral Blood Stem Cell Transplantation / adverse effects


21. Sréter L: [Therapy in Hodgkin disease and non-Hodgkin lymphomas]. Orv Hetil; 2009 Apr 5;150(14):651-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy in Hodgkin disease and non-Hodgkin lymphomas].
  • [Transliterated title] A Hodgkin- és a non-Hodgkin-lymphomák kezelése.
  • The therapy of malignant lymphoproliferative diseases has changed many times in recent years.
  • Treatment strategy of Hodgkin's disease is now based on risk adaptation, including not only the results of pretreatment diagnostic and prognostic factors but also the repeated PET/CT (restaging) made in the early treatment period.
  • Possible reduction of irradiation therapy may contribute to lower the risk of secondary tumors, which are common late complications of radiochemotherapy.
  • Autologous stem cell transplantation is the therapy of choice in chemosensitive relapsing patients.
  • In the heterogenic group of Non-Hodgkin Lymphomas, progression of indolent lymphomas (CLL, multiple myeloma, hairy cell leukemia, cutaneous lymphomas, etc.) is slow in case of natural course.
  • Their therapy is mostly palliative and complete remission with the latest treatment modalities is not possible.
  • Aggressive lymphomas are characterized with rapid progression and early death without treatment.Most of them respond to chemotherapy and irradiation.With an adequate therapy, 60-70% of patients reach complete remission (CR) and 40-50% of them remain in remission.
  • Using immune- and radioimmune therapy in indolent and aggressive NHL groups gives possibility to influence G0 tumor cells as well.
  • Their use in combination with classic chemotherapy leads to more complete remissions and better therapy results.
  • The introduction of routine PET/CT made the first and repeated staging of NHL more precise and contributed to more effective treatment.
  • Using autologous stem cell transplantation in chemosensitive patients may improve outcome in selected patients.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Neoplasms, Second Primary / prevention & control
  • [MeSH-minor] Disease Progression. Humans. Leukemia, Hairy Cell / diagnosis. Leukemia, Hairy Cell / therapy. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Multiple Myeloma / diagnosis. Multiple Myeloma / therapy. Neoplasm Staging. Positron-Emission Tomography. Remission Induction. Stem Cell Transplantation. Tomography, X-Ray Computed. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318337.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


22. Makishima H, Ito T, Kodama R, Asano N, Nakazawa H, Hirabayashi K, Nakamura S, Ota M, Akamatsu T, Kiyosawa K, Ishida F: Intestinal diffuse large B-cell lymphoma associated with celiac disease: a Japanese case. Int J Hematol; 2006 Jan;83(1):63-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal diffuse large B-cell lymphoma associated with celiac disease: a Japanese case.
  • Intestinal non-Hodgkin's lymphoma (NHL), especially the T-cell type, is well known to be associated with celiac disease (CD), an enteropathic disorder with a propensity for certain racial and genetic backgrounds.
  • CD is typically characterized by gastrointestinal (GI) symptoms, anti-transglutaminase antibodies in the sera, and microscopical findings of the intestinal mucosa, which resolve with a gluten-free diet (GFD).
  • In Asian populations, including the Japanese, CD and the associated NHL have been supposed to be quite rare, and studies concerning the frequency of CD or its relationship with NHL are scarce.
  • We describe a Japanese middle-aged man with intestinal diffuse large B-cell lymphoma associated with CD.
  • Following multi-combined chemotherapy, the patient's lymphoma has been in a state of complete response, and his GI symptoms have improved with a GFD.
  • This case suggests that the possibility of CD and its association with intestinal NHL should be kept in mind, even in Asian populations.
  • [MeSH-major] Celiac Disease / pathology. Intestinal Neoplasms / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology


23. Nakamura K, Sasaki M, Kunitake N, Kimura M, Watanabe T, Sasaki T, Terashima H, Kuwabara Y, Sakai S, Masuda K: Relapse patterns of localized non-Hodgkin's lymphoma of the head and neck after clinical remission: results of a strict follow-up procedure. Int J Clin Oncol; 2001 Dec;6(6):302-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse patterns of localized non-Hodgkin's lymphoma of the head and neck after clinical remission: results of a strict follow-up procedure.
  • BACKGROUND: No effective follow-up strategy for non-Hodgkin's lymphoma (NHL) has been identified to date.
  • The aim of this study was to assess the value of a strict follow-up procedure in patients with NHL after they showed clinical remission.
  • METHODS: One hundred and twenty-one patients with localized NHL of the head and neck who had achieved clinical remission after radiation therapy and/or chemotherapy were followed with a strict follow-up strategy (consisting of a schedule of frequent office visits, imaging studies, and blood tests, even if the patient was asymptomatic).
  • The other tests that initially indicated relapse included scheduled computed tomography scans (3 patients), scheduled gallium scans (2 patients), and serum lactate dehydrogenase levels (2 patients).
  • According to the Ann Arbor stage at relapse, 72.7% of the patients with symptomatic relapses were stage III or IV, while 70.6% of the patients with asymptomatic relapses were stage I or II.
  • CONCLUSIONS: These results indicate that a strict follow-up procedure is effective in detecting asymptomatic relapses, which generally involve a smaller tumor load than symptomatic relapses.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Central Nervous System Diseases / chemically induced. Female. Gallium. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Neoplasm Staging. Physical Examination. Remission Induction. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. GALLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11828950.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] CH46OC8YV4 / Gallium; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


24. Win N, Tiwari D, Keevil VL, Needs M, Lakhani A: Mixed-type autoimmune haemolytic anaemia: unusual cases and a case associated with splenic T-cell angioimmunoblastic non-Hodgkin's lymphoma. Hematology; 2007 Apr;12(2):159-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed-type autoimmune haemolytic anaemia: unusual cases and a case associated with splenic T-cell angioimmunoblastic non-Hodgkin's lymphoma.
  • The diagnosis of mixed-type autoimmune haemolytic anaemia (AIHA) is based on demonstrating the presence of "warm" IgG auto-antibody and "low titre" ( < 64 at 4 degrees C), "high thermal amplitude" (reacting at or >30 degrees C) "cold" IgM auto-antibody.
  • Mixed-type AIHA is uncommon.
  • Red cell agglutination on the peripheral blood film is a common finding in mixed-type AIHA and can lead, initially, to a mis-diagnosis of cold haemmagglutinin disease (CHAD).
  • Mixed-type AIHA is rare and can be idiopathic or secondary, often associated with systemic lupus erythematosus (SLE) and lymphoma.
  • In general, patients with mixed-type AIHA show a dramatic response to steroid therapy and frequently require few or no transfusions.
  • We report two unusual cases of mixed-type AIHA.
  • Case one was unusual as the patient developed AIHA while on steroid medication.
  • Case two, we believe, is the first reported case of splenic T cell angioimmunoblastic non-Hodgkins lymphoma (NHL) associated with mixed-type AIHA.
  • The patient failed to respond to steroids, intravenous immunoglobulin, chemotherapy and treatment with rituximab.
  • DAT tested with monospecific reagents, and thorough serological investigations is required to reach the diagnosis of mixed-type AIHA.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / etiology. Anti-Inflammatory Agents / adverse effects. Lymphoma, T-Cell / complications. Paraneoplastic Syndromes / etiology. Prednisolone / adverse effects. Splenic Neoplasms / complications
  • [MeSH-minor] Aged. Antibodies, Anti-Idiotypic / blood. Antibodies, Anti-Idiotypic / immunology. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Autoantibodies / blood. Autoantibodies / immunology. Combined Modality Therapy. Complement C3d / immunology. Coombs Test. Cryoglobulins / analysis. Cryoglobulins / immunology. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Erythrocyte Transfusion. Fatal Outcome. Female. Humans. Immunoglobulin G / blood. Immunoglobulin G / immunology. Immunoglobulin M / blood. Immunoglobulin M / immunology. Immunoglobulins, Intravenous / therapeutic use. Immunosuppressive Agents / therapeutic use. Immunotherapy. Male. Osteoarthritis / drug therapy. Prednisone / administration & dosage. Rituximab. Splenectomy. Temperature. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454198.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Autoantibodies; 0 / Cryoglobulins; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Immunoglobulins, Intravenous; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80295-45-0 / Complement C3d; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; COP protocol 2
  •  go-up   go-down


25. Kuruvilla J, Pond G, Tsang R, Gupta V, Lipton JH, Messner HA: Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma. Biol Blood Marrow Transplant; 2008 Jul;14(7):775-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma.
  • Allogeneic stem cell transplantation (Allo-SCT) remains an option for patients with follicular lymphoma (FL).
  • We performed a retrospective analysis to examine long-term disease control and treatment-related mortality (TRM) in a group of patients that underwent transplant for clinically high-risk disease.
  • Thirty-seven patients with indolent FL (follicular small cleaved [FSC], follicular mixed [FM] or FL grades 1 or 2 by WHO criteria) underwent allo-SCT.
  • Patients were in a chemosensitive remission at the time of SCT.
  • The median age at the time of transplant was 45 years (range: 24-58).
  • The median number of prior chemotherapy regimens was 3 (range: 1-6).
  • With a median follow-up of 63.5 months in survivors, the 5-year overall survival is 79.1% (95% confidence interval 66.3%-94.4%).
  • [MeSH-major] Graft vs Tumor Effect. Lymphoma, Follicular / therapy. Neoplasm Recurrence, Local / therapy. Stem Cell Transplantation / methods. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Age Factors. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Salvage Therapy / methods. Transplantation, Autologous

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541196.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Boes M, Pels H, Klockgether T, Koch A, Schlegel U: High-grade B-cell NHL of the brachial plexus followed by infiltration of the spinal cord. J Neurol; 2008 Jan;255(1):135-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade B-cell NHL of the brachial plexus followed by infiltration of the spinal cord.
  • [MeSH-major] Brachial Plexus Neuropathies / etiology. Brachial Plexus Neuropathies / pathology. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / pathology. Neoplasm Invasiveness / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Arm / innervation. Arm / physiopathology. Brachial Plexus / pathology. Brachial Plexus / physiopathology. Cavernous Sinus Thrombosis / etiology. Cavernous Sinus Thrombosis / pathology. Cavernous Sinus Thrombosis / physiopathology. Cranial Nerve Diseases / etiology. Cranial Nerve Diseases / pathology. Cranial Nerve Diseases / physiopathology. Fatal Outcome. Female. Ganglia, Spinal / pathology. Ganglia, Spinal / physiopathology. Humans. Magnetic Resonance Imaging. Middle Aged. Muscle Weakness / etiology. Muscle Weakness / physiopathology. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Spinal Cord / pathology. Spinal Cord / physiopathology. Spinal Nerve Roots / pathology. Spinal Nerve Roots / physiopathology. Treatment Failure

  • MedlinePlus Health Information. consumer health - Brachial Plexus Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1257-65 [10976700.001]
  • [Cites] Neurosurgery. 1997 Mar;40(3):618-21; discussion 621-2 [9055305.001]
  • [Cites] J Neurosurg. 2000 Jan;92(1):165-9 [10616097.001]
  • [Cites] Auris Nasus Larynx. 1999 Jul;26(3):337-42 [10419043.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4471-3 [14597745.001]
  • (PMID = 17994311.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


27. Kazanowska B, Wróbel G, Jaworski W, Bogusławska-Jaworska J, Jeleń M, Armata J, Balcerska A, Bubala H, Dluzniewska A, Kołecki P, Kowalczyk J, Kurylak A, Matysiak M, Ploszyńska A, Rokicka-Milewska R, Sońta-Jakimczyk D, Sopylo B, Stańczak E, Stefaniak MJ, Stefańska K, Wysocki M, Gacka M: [Abdominal presentation of B-cell non-Hodgkin's lymphoma (B-NHL) - surgical treatment and its results. Report of the Polish Paediatric Leukaemia/Lymphoma Study Group]. Med Wieku Rozwoj; 2000;4(1 Suppl 2):57-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Abdominal presentation of B-cell non-Hodgkin's lymphoma (B-NHL) - surgical treatment and its results. Report of the Polish Paediatric Leukaemia/Lymphoma Study Group].
  • The aim of this study was to analyse the effect of LMB-89 protocol and surgical procedure at initial laparotomy on the outcome in children with abdominal B-cell NHL.
  • There were 4% non responder patients.
  • The estimate EFS for all patients with AB-NHL is 81%, 85% for stage III and 73% for stage IV.
  • Major surgery in advanced stages is not recommended since it delays chemotherapy and fails to improve overall survival.
  • [MeSH-major] Abdominal Neoplasms / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / surgery
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Hydrocortisone / administration & dosage. Infant. Laparotomy. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Risk Factors. Time Factors. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12021463.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate; LMB89 protocol
  •  go-up   go-down


28. Verdonck LF, Notenboom A, de Jong DD, MacKenzie MA, Verhoef GE, Kramer MH, Ossenkoppele GJ, Doorduijn JK, Sonneveld P, van Imhoff GW: Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood; 2007 Apr 1;109(7):2759-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).
  • Optimal dose and timing of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy for aggressive non-Hodgkin lymphoma (NHL) is still an unresolved issue.
  • We assessed whether dose intensifications with cyclophosphamide and doxorubicin might improve outcome in younger patients with intermediate-risk aggressive NHL.
  • Although clinically relevant side effects occurred more often in the I-CHOP arm, treatment-related mortality was similar.
  • These data suggest that I-CHOP might be preferable to standard CHOP in younger patients with low-intermediate-risk aggressive NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Belgium. Child. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Netherlands. Prednisone / administration & dosage. Prednisone / adverse effects. Prognosis. Recombinant Proteins. Risk Factors. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17132720.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


29. Buadi FK, Micallef IN, Ansell SM, Porrata LF, Dispenzieri A, Elliot MA, Gastineau DA, Gertz MA, Lacy MQ, Litzow MR, Tefferi A, Inwards DJ: Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant; 2006 Jun;37(11):1017-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma.
  • To evaluate autologous stem cell transplant (ASCT) in older patients with intermediate grade non-Hodgkin's lymphoma (NHL), the Mayo Clinic Rochester BMT database was reviewed for all patients 60 years of age and older who received ASCT for NHL between September 1995 and February 2003.
  • Factors evaluated included treatment-related mortality (TRM), event-free survival (EFS) and overall survival (OS).
  • Treatment-related mortality (5.4%) was not significantly different when compared to a younger cohort (2.2%).
  • Autologous stem-cell transplant can be safely performed in patients 60 years or older with chemotherapy sensitive relapsed or first partial remission NHL.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633361.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Taskinen M, Jantunen E, Kosma VM, Bono P, Karjalainen-Lindsberg ML, Leppä S: Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy. Eur J Cancer; 2010 Sep;46(13):2506-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy.
  • Furthermore, accumulation of MCs in follicular lymphoma (FL) correlates with unfavourable prognosis after immunochemotherapy.
  • Here we investigated whether tumour vascularity is associated with MC content and outcome in FL patients treated with immunochemotherapy.
  • PATIENTS AND METHODS: Microvessel density (MVD) and MC content were determined immunohistochemically from pretreatment samples of 95 FL patients using CD31, CD34 and mast cell tryptase antibodies.
  • Gene expression data from a separate set of 24 FL patients were analysed for comparison.
  • All patients were treated with the combination of rituximab (R) and cyclophoshamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy.
  • In multivariate analyses, CD31+ MVD had prognostic value independently of Follicular Lymphoma Prognostic Index but not of MC content.
  • CONCLUSION: Vascularity is associated with MC content and outcome in R-CHOP-treated FL patients.
  • [MeSH-major] Antigens, CD31 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunotherapy / methods. Lymphoma, Follicular / therapy. Microvessels / pathology
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prednisone / administration & dosage. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20630741.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD31; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


31. Kang TY, Rybicki LA, Bolwell BJ, Thakkar SG, Brown S, Dean R, Sekeres MA, Advani A, Sobecks R, Kalaycio M, Pohlman B, Sweetenham JW: Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma. Bone Marrow Transplant; 2007 Nov;40(10):973-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma.
  • Autologous stem-cell transplantation (ASCT) has been used in follicular lymphoma (FL) to achieve durable responses in first remission or in the relapsed or refractory settings.
  • Addition of rituximab to chemotherapy for FL has been shown to improve survival.
  • The impact of prior therapy with rituximab upon the effectiveness of high-dose therapy (HDT) and ASCT in patients with FL is unknown.
  • We retrospectively reviewed consecutive patients with FL who underwent HDT and ASCT.
  • Patients were categorized according to prior therapy with rituximab.
  • Outcomes were compared between groups in all patients and in a well-matched subset.
  • The rituximab-naive group had a median overall survival (OS) that was not reached during follow-up, with a median relapse-free (RFS) survival of 49.9 months.
  • Survivals were not significantly different in this group or in the well-matched subset.
  • In conclusion, these results suggest that the use of rituximab-based regimens for the treatment of FL does not compromise the effectiveness of HDT and ASCT as a salvage strategy in patients with FL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Follicular / therapy. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17873917.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


32. Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW: Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol; 2005 Sep;55(3):231-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This large population-based study focuses on the prognostic role of increasing age and co-morbidity in cancer patients diagnosed in the southern Netherlands.
  • Older patients (with serious co-morbidity) with non-small cell lung cancer or prostate cancer underwent surgery less often than younger patients.
  • Elderly with stage III colon cancer, small cell lung cancer, FIGO II or III ovarian cancer or non-Hodgkin's lymphoma (NHL) received (adjuvant) chemotherapy less often, probably because of the higher rate of haematological complications.
  • Administration of adjuvant radiotherapy decreased with age and co-morbidity in patients with rectal cancer, limited small cell lung cancer or breast cancer.
  • In general, elderly did not suffer from more complications than younger patients, except for cardiac complications (colorectal cancer and NHL) and postoperative death (non-small cell lung cancer).
  • For most tumours relative survival was lower for the elderly, except for patients with colon cancer, prostate cancer or indolent NHL.
  • Co-morbidity had an independent prognostic effect, except for tumours with a very poor prognosis.
  • Future prospective studies should investigate whether the guidelines for cancer treatment should be adjusted for elderly with serious co-morbidity.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15979890.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


33. Matković S, Jelić S, Manojlović N, Milanović N: Non-Hodgkin's lymphomas with primary localization in large bowel and rectum. Med Sci Monit; 2000 Jan-Feb;6(1):68-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas with primary localization in large bowel and rectum.
  • From 1989, at the Department of Medical Oncology of the Institute for Oncology and Radiology in Belgrade, seven patients with primary NHL of large bowel and rectum have been observed and treated, 3 males and 4 females.
  • In 3 patients an urgent laparotomy without previous diagnostic procedures was performed, while 4 patients had laparotomy only after radiographic and endoscopic diagnosis of a tumor.
  • Five patients had lymphoma localized in cecoascedental part of colon (2 centroblastic, 1 lymphoplasmocytic, 1 Burkitt and 1 Burkitt's like), 1 patient had it in the transversal part of colon (centroblastic), and one in the rectum (diffuse centrocytic).
  • By further investigation, in 2 cases with localization within transversal part of colon and rectum no other sites of NHL were found.
  • Out of 5 patients with localization within cecum or ascendent part of colon, in 2 cases with Burkitt/Burkitt-like histology retroperitoneal lymphadenopathy were found, one female had NHL central propagation, and the other one lymphoma generalization.
  • Both patients had early death from lymphoma.
  • The remaining three patients following chemotherapy with the ProMACE regimen (as they too had a post laparotomy stage II disease) achieved a complete response lasting for 36+, 41+ and 66+ months.
  • Since the median survival in our group of patients is at the moment 41+ months and the median has not yet been reached, our experience does not confirm literature data claiming bad prognosis of primary NHL of the colon and rectum.
  • A long disease free survival can be obtained in these patients either with surgery only or surgery + chemotherapy, depending on disease stage and possibly initial topographic localization.
  • [MeSH-major] Colonic Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11208286.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


34. Bradt BM, DeNardo SJ, Mirick GR, DeNardo GL: Documentation of idiotypic cascade after Lym-1 radioimmunotherapy in a patient with non-Hodgkin's lymphoma: basis for extended survival? Clin Cancer Res; 2003 Sep 1;9(10 Pt 2):4007S-12S
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Documentation of idiotypic cascade after Lym-1 radioimmunotherapy in a patient with non-Hodgkin's lymphoma: basis for extended survival?
  • PURPOSE: The purpose of this study was to examine idiotypic cascade mechanisms in the plasma of a prolonged survivor patient with aggressive non-Hodgkin's lymphoma (NHL).
  • It is a follow-up to previously published seminal studies by this laboratory showing survival benefit associated with radioimmunotherapy in NHL patients.
  • EXPERIMENTAL DESIGN: Plasma from a NHL patient treated with Lym-1 was precipitated with ammonium sulfate and octanoic acid, followed by immunoadsorbant chromatography with solid phase Lym-1 monoclonal antibody to purify Ab2.
  • Both showed ability to compete with the binding of Lym-1 to its tumor cell target, and Ab3 showed ability to induce antibody-dependent cellular cytotoxicity.
  • CONCLUSIONS: This study offers direct evidence for initiation of a multilevel idiotypic cascade in a patient undergoing passive monoclonal antibody therapy for NHL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / therapy. Radioimmunotherapy / methods
  • [MeSH-minor] Ammonium Sulfate / pharmacology. Animals. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / chemistry. Binding, Competitive. Caprylates / pharmacology. Cell Line, Tumor. Chromatography. Disease-Free Survival. Dose-Response Relationship, Drug. Electrophoresis, Polyacrylamide Gel. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoglobulin Idiotypes. Mice. Middle Aged. Time Factors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OCTANOIC ACID .
  • Hazardous Substances Data Bank. SODIUM OCTANOATE .
  • Hazardous Substances Data Bank. Ammonium sulfate .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14506201.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-47829
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Caprylates; 0 / Immunoglobulin Idiotypes; 0 / Lym-1 monoclonal antibody; 124-07-2 / octanoic acid; SU46BAM238 / Ammonium Sulfate
  •  go-up   go-down


35. Ulrickson M, Aldridge J, Kim HT, Hochberg EP, Hammerman P, Dube C, Attar E, Ballen KK, Dey BR, McAfee SL, Spitzer TR, Chen YB: Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Biol Blood Marrow Transplant; 2009 Nov;15(11):1447-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
  • High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been established as a standard form of therapy for patients with non-Hodgkin lymphoma (NHL).
  • While many high-dose chemotherapy combinations are used, no single regimen has proved superior over another.
  • Here, we report our single center's experience in patients with NHL undergoing ASCT with the combination of busulfan and cyclophosphamide (Bu/Cy).
  • This study is a retrospective analysis of 78 consecutive patients with NHL who underwent ASCT with Bu/Cy at Massachusetts General Hospital Cancer Center.
  • A total of 78 patients with NHL underwent ASCT with Bu/Cy preparative therapy between 1996 and 2006.
  • The 100-day treatment-related mortality (TRM) was 1%.
  • Our data indicate that in patients with NHL undergoing ASCT, Bu/Cy has efficacy and toxicity comparable to that of other reported regimens.
  • [MeSH-major] Busulfan / administration & dosage. Cyclophosphamide / administration & dosage. Lymphoma, Non-Hodgkin / surgery. Myeloablative Agonists / administration & dosage. Peripheral Blood Stem Cell Transplantation. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Atrial Fibrillation / epidemiology. Atrial Fibrillation / etiology. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Hepatic Veno-Occlusive Disease / epidemiology. Hepatic Veno-Occlusive Disease / etiology. Humans. Infection / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Postoperative Complications / epidemiology. Retrospective Studies. Salvage Therapy. Transplantation, Autologous. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822305.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloablative Agonists; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  •  go-up   go-down


36. Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, Darif M, Macklis R, Vo K, Wiseman GA: Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer; 2007 May 1;109(9):1804-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.
  • BACKGROUND: Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non-Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined.
  • METHODS: Data on patients with recurring NHL treated with yttrium Y 90 ibritumomab tiuxetan in 4 clinical trials were reviewed to identify patients with a long-term response, defined as a time to progression of 12 months or longer.
  • At a median follow-up of 53.5 months (range, 12.7-88.9) the median duration of response was 28.1 months and the median time to progression was 29.3 months.
  • A third of these patients had been treated with at least 3 previous therapies, and 37% of them had not responded to their last therapy.
  • The findings in patients with follicular lymphoma (n=59) were similar to those in the overall population of long-term responders.
  • CONCLUSIONS: A single dose of 90Y ibritumomab tiuxetan can produce durable responses and prolonged overall survival in a substantial number of patients in whom previous therapies have failed.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Drug Resistance, Neoplasm. Humans. Immunoconjugates / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Rituximab

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 American Cancer Society
  • (PMID = 17380530.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunoconjugates; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


37. Kucuk O, Young ML, Habermann TM, Wolf BC, Jimeno J, Cassileth PA: Phase II trail of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) Study. Am J Clin Oncol; 2000 Jun;23(3):273-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trail of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) Study.
  • Patients with non-Hodgkin's lymphoma (NHL) who fail initial therapy have a poor prognosis.
  • We conducted a phase II study to determine the efficacy and toxicity of didemnin B, a non-myelosuppressive marine compound, in patients with NHL who relapsed or progressed after receiving one or two previous chemotherapy regimens.
  • Twenty-nine patients had intermediate or high grade (IG/HG) disease and 22 patients had low grade (LG) disease.
  • Patients with IG/HG disease had a median time to treatment failure (TTF) of 1.6 months and a median survival of 8.0 months.
  • There were five grade V, 12 grade IV, and 57 grade III toxicities.
  • Didemnin B appears to have modest activity in low grade NHL.
  • However, the drug has considerable toxicity in this population of patients.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Depsipeptides. Lymphoma, Non-Hodgkin / drug therapy. Peptides, Cyclic / adverse effects. Peptides, Cyclic / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10857892.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA06594; United States / NCI NIH HHS / CA / CA13650; United States / NCI NIH HHS / CA / CA23318; etc
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Depsipeptides; 0 / Peptides, Cyclic; 77327-04-9 / didemnins
  •  go-up   go-down


38. Ghesquières H, Berger F, Felman P, Callet-Bauchu E, Bryon PA, Traverse-Glehen A, Thieblemont C, Baseggio L, Michallet AS, Coiffier B, Salles G: Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol; 2006 Nov 20;24(33):5234-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis.
  • PURPOSE: Some diffuse large B-cell lymphomas (DLBCL) present at diagnosis with associated morphologic features of small B-cell non-Hodgkin's lymphoma (NHL) and may arise from the transformation of a previously unknown indolent low-grade lymphoma.
  • The characteristics and prognosis of these particular DLBCL are not well known.
  • PATIENTS AND METHODS: The strict morphologic review of consecutive DLBCL patients diagnosed over 12 years in our department (Hematology Department, Centre Hospitalier Lyon-Sud, Lyon, France) allowed to retrieve 60 DLBCL that could be have occurred from the transformation of marginal zone B-cell NHL (32 patients), follicular NHL (22 patients), and small lymphocytic NHL (6 patients).
  • We compared them to 180 matched patients of de novo DLBCL.
  • Complete remission with multidrug chemotherapy regimens was achieved in 60% of the patients, but 48% relapsed: 28% with aggressive and 20% with indolent histology, respectively.
  • The matched-control analysis showed that patients with transformed NHL at diagnosis had lower complete response to chemotherapy (P = .004) and higher progression rate (P = .03), whereas no difference was observed in OS (P = .21).
  • CONCLUSION: Compared to de novo DLBCL, transformed NHL at diagnosis have similar overall survival but lower complete response to initial treatment and higher risk of indolent relapses.
  • [MeSH-major] Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Case-Control Studies. Cell Transformation, Neoplastic / pathology. Cytogenetic Analysis. Disease-Free Survival. Female. Humans. Immunophenotyping. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043351.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Peng YL, Huang HQ, Lin XB, Xia ZJ, Li YH, Wang W, He YJ, Pan ZH, Jiang WQ, Guan ZZ: [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen]. Ai Zheng; 2004 Aug;23(8):943-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
  • BACKGROUND & OBJECTIVES: The biological behavior of peripheral T-cell lymphoma (PTCL) are different from that of B-cell non-Hodgkin's lymphoma (NHL).
  • It shows low chemosensitivity, high incidence of relapse, poor prognosis, and has no standard chemotherapy regimen.
  • According to WHO classification criteria, 21 cases of PTCL concluded 7 peripheral T-cell lymphoma unspecified (PTCL-U), 7 NK/T-cell lymphoma (NK/TCL), 5 anaplastic large cell lymphoma (ALCL), 1 Mycosis fungoides/Sezary syndrome (MF/SS), and 1 subcutaneous panniculitis-like T-cell lymphoma (SPTCL).
  • RESULTS: Of 21 patients, 20 were eligible to evaluate treatment efficacy.
  • Seventy cycles of chemotherapy were administered to 21 patients.
  • Major toxicity was myelosuppression, the incidences of grade III-IV neutropenia, thrombocytopenia, and anemia were 34.3%, 14.3%, and 7.1%.
  • Other toxicities were mild, no treatment-related mortality occurred.
  • CONCLUSION: EPOCH was effective and well tolerant for the patients with PTCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neutropenia / chemically induced. Prednisone / administration & dosage. Prednisone / adverse effects. Remission Induction. Survival Rate. Thrombocytopenia / chemically induced. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15301720.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; EPOCH protocol
  •  go-up   go-down


40. Levine AM, Tulpule A, Espina B, Sherrod A, Boswell WD, Lieberman RD, Nathwani BN, Welles L: Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol; 2004 Jul 1;22(13):2662-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.
  • PURPOSE: To evaluate the safety and efficacy of liposomal doxorubicin (Myocet; Medeus Pharma Ltd, Herts,UK) when substituted for doxorubicin in the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma (AIDS-NHL).
  • All patients received concurrent highly active antiretroviral therapy.
  • NHL tissues were evaluated for multidrug resistance (MDR-1) expression.
  • Effective HIV viral control during chemotherapy was associated with significantly improved survival (P =.027), but CRs were attained independent of HIV viral control.
  • CONCLUSION: Liposomal doxorubicin in combination with cyclophosphamide, vincristine, and prednisone is active in AIDS-NHL, with complete remissions achieved in 75% independent of HIV viral control or tissue MDR-1 expression.
  • HIV viral control is associated with a significant improvement in survival.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / administration & dosage. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] CD4 Lymphocyte Count. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Humans. Liposomes. P-Glycoprotein / biosynthesis. Prednisone / administration & dosage. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Viral Load

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15226333.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


41. Ogura M: [Adriamycin (doxorubicin)]. Gan To Kagaku Ryoho; 2001 Oct;28(10):1331-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anthracyclines have been in clinical practice since the 1960s and represent one of the most commonly used classes of anticancer drugs.
  • Doxorubicin (adriamycin) is one of the first anthracyclines in clinical use, has a broad anti-tumor spectrum, and has been used against hematopoietic malignancies such as lymphoma, myeloma and leukemia, and solid tumors such as breast cancer, ovarian cancer and sarcomas.
  • There are two chemotherapeutic regimens containing doxorubicin that have been established as the state of the art therapy against malignant lymphomas.
  • One is ABVD therapy for Hodgkin's lymphoma, and the other is CHOP therapy for aggressive non-Hodgkin's lymphoma (NHL).
  • In these regimens as well as the regimen for breast cancer, doxorubicin is delivered by bolus intravenous infusion for 30 minutes to one hour.
  • VAD regimen for myeloma, and EPOCH regimen for relapsed aggressive NHL have been reported and used.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Doxorubicin / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Multiple Myeloma / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Humans. Infusions, Intravenous

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11681238.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin
  • [Number-of-references] 21
  •  go-up   go-down


42. Venkitaraman R, George MK: Primary non Hodgkin's lymphoma of the lacrimal sac. World J Surg Oncol; 2007;5:127
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non Hodgkin's lymphoma of the lacrimal sac.
  • BACKGROUND: Primary Non Hodgkin's Lymphoma (NHL) of the lacrimal sac is rare.
  • RESULTS: Computerised tomography showed a mass involving the left lacrimal sac.
  • Histopathological examination revealed a diffuse large B cell NHL.
  • Immunohistological examination demonstrated B cell origin.
  • Chemotherapy could not be administered due to co morbid conditions.
  • The patient was treated with radiotherapy to a dose of 45 Gy in 25 fractions.
  • CONCLUSION: Primary radiotherapy is a treatment option with curative potential for localized NHL of the lacrimal sac and may be considered in patients who cannot tolerate appropriate chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]
  • [Cites] Tumori. 2002 Nov-Dec;88(6):530-1 [12597152.001]
  • [Cites] Am J Clin Oncol. 1992 Oct;15(5):422-7 [1524043.001]
  • [Cites] Br J Ophthalmol. 2006 Aug;90(8):1004-9 [16672329.001]
  • [Cites] Radiother Oncol. 1991 Sep;22(1):36-44 [1947211.001]
  • [Cites] Can J Ophthalmol. 1988 Feb;23(1):34-7 [3349362.001]
  • [Cites] Radiother Oncol. 1985 Nov;4(3):211-23 [3909240.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Jul;10(7):1013-9 [6430846.001]
  • [Cites] Ophthalmology. 1978 Dec;85(12):1282-7 [745835.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1976 Nov-Dec;1(11-12):1099-105 [791910.001]
  • [Cites] Otolaryngol Head Neck Surg. 1994 Nov;111(5):647-51 [7970805.001]
  • [Cites] Am J Ophthalmol. 1994 Nov 15;118(5):650-8 [7977578.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1095-103 [8083079.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Apr 30;26(1):59-66 [8482631.001]
  • [Cites] Radiother Oncol. 1996 Jan;38(1):13-8 [8850421.001]
  • [Cites] Cancer. 1997 Dec 1;80(11):2151-5 [9392338.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2002 Jul;18(4):242-6 [12142754.001]
  • (PMID = 17986344.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2186337
  •  go-up   go-down


43. Multani P, White CA, Grillo-López A: Non-Hodgkin's lymphoma: review of conventional treatments. Curr Pharm Biotechnol; 2001 Dec;2(4):279-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma: review of conventional treatments.
  • The non-Hodgkin's lymphomas are a diverse groups of lymphoid neoplasms that collectively rank fifth in cancer incidence and mortality.
  • Conventional treatment for patients with newly-diagnosed non-Hodgkin's lymphoma (NHL) includes radiation or chemotherapy.
  • In addition, those with asymptomatic low-grade disease may follow a "watch and wait" approach.
  • Single agent oral alkylating therapy and CVP (cyclophosphamide, vincristine, and prednisone) have become a mainstay of treatment for low-grade NHL.
  • High intensity chemotherapy consisting of the anthracycline, doxorubicin along with cyclophosphamide, vincristine and prednisone (CHOP) is offered as standard treatment for intermediate-grade NHL.
  • Following relapse, salvage therapy rarely results in long-term survival in patients with low-grade NHL.
  • For patients with intermediate-grade NHL who relapse after or do not respond to first-line treatment, a range of combination regimens can be offered, composed of non-cross resistant drugs not typically used during first-line treatment.
  • However, less than half of patients with intermediate-grade disease achieve prolonged disease-free survival.
  • With today's' conventional treatments, cure is only a possibility for a minority of patients with intermediate-grade disease and a limited group of patients with indolent NHL who are diagnosed at early stages.
  • Novel approaches to treatment are therefore needed.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation. Combined Modality Therapy. Humans. Prognosis. Survival Analysis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11762410.001).
  • [ISSN] 1389-2010
  • [Journal-full-title] Current pharmaceutical biotechnology
  • [ISO-abbreviation] Curr Pharm Biotechnol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 139
  •  go-up   go-down


44. Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, MacLennan K, Staab-Renner E, Kalmus J, Schott A, Teodorovic I, Negrouk A, van Glabbeke M, Marcus R: Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. J Clin Oncol; 2006 Apr 1;24(10):1590-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.
  • PURPOSE: To compare the efficacy and safety of fludarabine phosphate with cyclophosphamide, vincristine, and prednisone (CVP) in 381 previously untreated, advanced-stage, low-grade (lg) non-Hodgkin's lymphoma (NHL) patients in a phase III, multicenter study.
  • PATIENTS AND METHODS: Between 1993 and 1997, patients were randomly assigned to treatment with either fludarabine (25 mg/m2 intravenously [IV] daily for 5 days every 4 weeks) or CVP (cyclophosphamide 750 mg/m2 IV on day 1; vincristine, 1.4 mg/m2 IV on day 1; and prednisone, 40 mg/m2 orally on days 1 through 5 every 4 weeks).
  • Complete response (CR) rates in the ITT population were also higher after fludarabine treatment.
  • There were no statistically significant differences in time to progression (TTP), time to treatment failure (TTF), and overall survival (OS) between treatment groups.
  • Combination therapies incorporating fludarabine are now being further evaluated as first-line therapy in follicular NHL.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Vidarabine Phosphate / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / therapeutic use. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prospective Studies. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575010.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 106XV160TZ / Vidarabine Phosphate; 1X9VK9O1SC / fludarabine phosphate; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; COP protocol 2
  •  go-up   go-down


45. Cooper AC, Karp RM, Clark EJ, Taghizadeh NR, Hoyt JG, Labenski MT, Murray MJ, Hannig G, Westlin WF, Thompson CD: A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo. Clin Cancer Res; 2006 Apr 15;12(8):2583-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo.
  • It has recently been reported that MetAP-2 is highly expressed in germinal center B cells and germinal center-derived non-Hodgkin's lymphomas (NHL), suggesting an important role for MetAP-2 in proliferating B cells.
  • Therefore, we determined the importance of MetAP-2 in normal and transformed germinal center B cells by evaluating the effects of MetAP-2 inhibition on the form and function of germinal centers and germinal center-derived NHL cells.
  • EXPERIMENTAL DESIGN: To examine the activity of PPI-2458 on germinal center morphology, spleen sections from cynomolgus monkeys treated with oral PPI-2458 were analyzed.
  • Antiproliferative activity of PPI-2458 was assessed on germinal center-derived NHL lines in culture.
  • A MetAP-2 pharmacodynamic assay was used to determine cellular MetAP-2 inhibition following PPI-2458 treatment.
  • Finally, inhibition of MetAP-2 and proliferation by PPI-2458 was examined in the human SR NHL line in culture and in implanted xenografts.
  • RESULTS: Oral PPI-2458 caused a reduction in germinal center size and number in lymphoid tissues from treated animals.
  • PPI-2458 potently inhibited growth (GI(50) = 0.2-1.9 nmol/L) of several NHL lines in a manner that correlated with MetAP-2 inhibition.
  • CONCLUSIONS: These results show the potent antiproliferative activity of PPI-2458 on NHL lines in vitro and oral antitumor activity in vivo and suggest the therapeutic potential of PPI-2458 as a novel agent for treatment of NHL should be evaluated in the clinical setting.
  • [MeSH-major] Aminopeptidases / antagonists & inhibitors. Cell Proliferation / drug effects. Epoxy Compounds / pharmacology. Lymphoma, Non-Hodgkin / drug therapy. Metalloendopeptidases / antagonists & inhibitors. Valine / analogs & derivatives
  • [MeSH-minor] Animals. B-Lymphocytes / drug effects. B-Lymphocytes / pathology. Blotting, Western. Cell Line, Tumor. Dose-Response Relationship, Drug. Female. Germinal Center / drug effects. Germinal Center / pathology. Humans. Lymphocyte Count. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Macaca fascicularis. Mice. Mice, SCID. Proto-Oncogene Proteins c-bcl-2 / metabolism. Time Factors. Xenograft Model Antitumor Assays / methods

  • Hazardous Substances Data Bank. L-Valine .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638869.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epoxy Compounds; 0 / PPI 2458; 0 / Proto-Oncogene Proteins c-bcl-2; EC 3.4.11.- / Aminopeptidases; EC 3.4.11.18 / methionine aminopeptidase 2; EC 3.4.24.- / Metalloendopeptidases; HG18B9YRS7 / Valine
  •  go-up   go-down


46. Ma S, Sheng X, Luo R, Li A: [Gemcitabine in the treatment of relapsed or refractory non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2002 Nov;24(6):619-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gemcitabine in the treatment of relapsed or refractory non-Hodgkin's lymphoma].
  • OBJECTIVE: To evaluate the efficacy and drug-related toxicity of combined gemcitabine, cisplatin, and prednisone for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).
  • METHODS: Fifteen patients with histologically confirmed relapsed or refractory aggressive NHL were included in this study.
  • Four patients' symptoms disappeared, and 1 in 6 patients was alleviated of type B symptoms.
  • Drug-related toxic effects of chemotherapy were mild gastrointestinal reactions in most patients and severe bone marrow depression in very few patients.
  • This protocol is worthy to be warranted as salvage for relapsed or refractory aggressive NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Lymphoma, Non-Hodgkin / drug therapy. Secondary Prevention
  • [MeSH-minor] Adolescent. Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Cisplatin / administration & dosage. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Salvage Therapy

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12667341.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone
  •  go-up   go-down


47. Tinmouth A, Zanke B, Imrie KR: Fludarabine in alkylator-resistant follicular non-Hodgkin's lymphoma. Leuk Lymphoma; 2001 Mar;41(1-2):137-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine in alkylator-resistant follicular non-Hodgkin's lymphoma.
  • Follicular small cell and follicular mixed small and large cell lymphoma (FL) are incurable with conventional chemotherapy, and generally follow a relapsing course, eventually becoming resistant to first-line therapy with alkylating agents.
  • Fludarabine is a novel chemotherapeutic agent that is effective in FL, but its role in alkylator-resistant disease remains unclear.
  • We conducted a retrospective review of all patients with alkylator-resistant FL treated with fludarabine.
  • Patients were identified from pharmacy records and included if they fulfilled criteria for alkylator-resistant FL.
  • Resistance was defined as failure to achieve a partial response, progression while on therapy, or relapse within six months of completing therapy.
  • Seventeen patients met the criteria of alkylator-resistant FL and were included in the analysis.
  • Four patients underwent subsequent autologous stem cell transplantation; all required additional salvage chemotherapy for post-fludarabine relapses.
  • Fludarabine produces partial responses in patients with advanced refractory FL; however, the duration of the response limits its utility in alkylator-resistant disease.
  • [MeSH-major] Drug Resistance, Neoplasm / physiology. Lymphoma, Follicular / drug therapy. Vidarabine / administration & dosage
  • [MeSH-minor] Actuarial Analysis. Adult. Aged. Disease-Free Survival. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Transplantation, Autologous. Treatment Outcome


48. Baecklund E, Sundström C, Ekbom A, Catrina AI, Biberfeld P, Feltelius N, Klareskog L: Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum; 2003 Jun;48(6):1543-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma.
  • OBJECTIVE: Patients with rheumatoid arthritis (RA) have an increased risk of developing malignant lymphoma.
  • It is not clear whether the increase is confined to certain subtypes of lymphomas.
  • Immunosuppressive therapy and Epstein-Barr virus (EBV) have been linked to the development of these lymphomas.
  • To gain information about the baseline pattern of lymphoma subtypes in RA before the current widespread use of immunosuppressive drugs, we examined the distribution of lymphoma subtypes and the presence of EBV in a cohort of RA patients with a low frequency and duration of treatment with immunosuppressive drugs.
  • METHODS: By linking data from the Swedish Hospital Discharge Register and the Swedish Cancer Register, 42 cases of lymphoma were identified among 11683 patients with RA in the Uppsala Health Care Region between 1964 and 1984.
  • The medical records and paraffin-embedded lymphoma tissues were collected, and the lymphomas were reclassified using the World Health Organization classification.
  • RESULTS: Tissues from 35 patients were reviewed.
  • Non-Hodgkin's lymphoma (NHL) was found in 33 patients and Hodgkin's lymphoma in 2 patients.
  • There was an increased frequency of diffuse large B cell lymphoma (DLBCL) (22 of 33 NHL patients, 67%) compared with that in the general population (30-40%).
  • EBV was detected in 5 of 30 examined lymphomas from patients (17%).
  • Twenty of the 22 DLBCL patients had RA with medium or high inflammatory activity, and 6 had been treated with a disease-modifying antirheumatic drug for >or=1 year.
  • CONCLUSION: The findings of this study suggest an increased incidence of one specific lymphoma subtype, DLBCL, in RA patients, as well as a possible association with RA disease activity.
  • [MeSH-major] Arthritis, Rheumatoid / complications. Lymphoma, B-Cell / etiology. Lymphoma, Large B-Cell, Diffuse / etiology. Registries


49. Neth O, Seidemann K, Jansen P, Mann G, Tiemann M, Ludwig WD, Riehm H, Reiter A: Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol; 2000 Jul;35(1):20-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90.
  • BACKGROUND: Precursor B-cell lymphoblastic lymphoma (PBLL) is a rare subtype of childhood non-Hodgkin lymphoma (NHL).
  • The purpose of our study was to investigate frequency and clinicopathological features of PBLL in children and to test prospectively the efficacy of an ALL-type therapy for treatment of these patients.
  • PROCEDURE: From October, 1986, to March, 1995, 1,075 patients up to 18 years of age suffering from all kinds of NHL were registered in the two consecutive multicenter studies NHL-BFM 86 and 90.
  • Twenty-one PBLL patients were treated according to a BFM-ALL-type protocol: an eight-drug induction over 9 weeks was followed by an 8-week consolidation including methotrexate 5 g/m(2) x4.
  • Patients in stages I and II continued with maintenance up to a total therapy duration of 24 months, whereas patients in stages III and IV received an additional eight-drug intensification and cranial radiotherapy (12 Gy for prophylaxis) after consolidation.
  • Six PBLL patients were treated according to the BFM-protocol for B-NHL, stratified according to stage and tumor load and consisiting of two to six 5-day courses of chemotherapy.
  • Stages (St. Jude) were: I (n = 3), II (n = 7), III (n = 9), and IV (n = 8).
  • With a median follow-up time of 4.
  • 25 years, the estimated probability for event-free survival (pEFS) at 10 years for the total group was 0.73 (SE 0.10).
  • Five patients (2, 1, 1, and 1 patients at stages I, II, III, and IV, respectively) relapsed: 2 of 21 patients who were treated according to the ALL strategy and 3 of 6 who were treated according to the B-NHL-protocol.
  • CONCLUSIONS: PBLL accounts for 2.5% of childhood NHL.
  • An ALL-type therapy strategy appears to be superior to a short-pulse B-NHL protocol.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adolescent. Asparaginase / administration & dosage. Austria / epidemiology. B-Lymphocytes. Child. Child, Preschool. Cohort Studies. Daunorubicin / administration & dosage. Disease-Free Survival. Female. Germany / epidemiology. Humans. Infant. Male. Multicenter Studies as Topic. Neoplasm Staging. Prednisone / administration & dosage. Prospective Studies. Registries. Survival Analysis. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10881003.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


50. Webb MS, Saltman DL, Connors JM, Goldie JH: A literature review of single agent treatment of multiply relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma; 2002 May;43(5):975-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A literature review of single agent treatment of multiply relapsed aggressive non-Hodgkin's lymphoma.
  • To analyze the available literature describing the treatment of relapsed aggressive non-Hodgkin's lymphoma (NHL) with single-agent chemotherapies, several comprehensive electronic and manual inspections of the literature were performed for the period from 1966 to the present.
  • Each paper was examined to capture the following data: study type; patient demographics and characteristics; study endpoints, including responses, and method used to evaluate response; toxicities, and the power of the study.
  • A wide variety of single-agent protocols continue to be studied, indicating no currently accepted standard therapy in this patient population.
  • The majority of trials were small, uncontrolled studies that used widely varying inclusion/exclusion criteria and had limited reporting of histology, response, prior treatments, and other key parameters.
  • We were able to find only four agents, etoposide, vincristine, vinorelbine and possibly rituximab, with sufficient reproducible evidence to suggest greater than 30% activity (CR + PR rate) when given to patients with second or greater relapse of aggressive NHL.
  • The advantages that would be brought by an active non-myelosuppressive agent for patients having this condition emerge clearly from this review.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12148908.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 51
  •  go-up   go-down


51. Mohile NA, Deangelis LM, Abrey LE: The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol; 2008 Apr;10(2):223-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of body FDG PET in staging primary central nervous system lymphoma.
  • (18)F-Fluorodeoxyglucose (FDG) PET has become an important tool in the management of non-Hodgkin's lymphoma (NHL), but its role in the evaluation of primary CNS lymphoma (PCNSL) has not been established.
  • The records of 166 PCNSL patients seen at Memorial Sloan-Kettering Cancer Center were examined.
  • Clinical data were reviewed to determine FDG PET results and their influence on therapy.
  • NHL was found in 11% of all patients, 7% of patients at diagnosis, and 27% of patients at CNS relapse.
  • Four percent had a second systemic neoplasm.
  • Workup with conventional staging did not reveal systemic disease, and in 8% of patients, body FDG PET was the only abnormal diagnostic exam suggestive of lymphoma.
  • FDG PET findings altered patient treatment and resulted in additional chemotherapy, surgery, or radiotherapy.
  • Our findings suggest that FDG PET may be more sensitive than conventional body staging and may disclose higher rates of concomitant systemic disease at PCNSL diagnosis.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Lymphoma / pathology. Lymphoma / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1999 Jul;43(3):231-6 [10563428.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):571-8 [17242397.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):793-800 [11843811.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):325-9 [14647988.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):939-47 [2914300.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):635-43 [1548527.001]
  • [Cites] J Neurooncol. 1995;25(1):67-71 [8523091.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4643-51 [15837966.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4577-80 [15837974.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):611-27, v [16083826.001]
  • [Cites] Nucl Med Commun. 2006 Jan;27(1):11-5 [16340718.001]
  • [Cites] N Engl J Med. 2006 Feb 2;354(5):496-507 [16452561.001]
  • [Cites] Haematologica. 2006 Apr;91(4):522-9 [16585017.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4754-7 [16966685.001]
  • [Cites] J Neurooncol. 2006 Nov;80(2):159-65 [16699873.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):11055-61 [17108145.001]
  • [Cites] Ann Hematol. 2007 Jan;86(1):9-15 [17021839.001]
  • [Cites] Br J Radiol. 2000 May;73(869):482-7 [10884743.001]
  • (PMID = 18287338.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2613825
  •  go-up   go-down


52. Fukuno K, Tsurumi H, Yamada T, Oyama M, Moriwaki H: Graft failure due to hemophagocytic syndrome after autologous peripheral blood stem cell transplantation. Int J Hematol; 2001 Feb;73(2):262-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft failure due to hemophagocytic syndrome after autologous peripheral blood stem cell transplantation.
  • Hemophagocytic syndrome (HPS) after hematopoietic stem cell transplantation can occasionally cause graft failure.
  • We describe a female patient with B-cell non-Hodgkin's lymphoma (NHL) with graft failure due to HPS 12 days after autologous peripheral blood stem cell transplantation (PBSCT).
  • Autologous PBSCT was carried out during unconfirmed/uncertain complete remission according to the Cotswolds classification after 6 cycles of biweekly (cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy and 3 courses of salvage chemotherapy including etoposide.
  • The patient developed a high fever on day 2 post-PBSCT.
  • Her white blood cell count rose to 0.9 x 10(9)/L on day 10 post-PBSCT, but then began to decrease.
  • Although high-dose methylprednisolone therapy was continued, her white blood cell count further decreased to 0.3 x 10(9)/L, and the patient died of multiple organ failure on day 29 post-PBSCT.
  • A computed tomography scan did not identify recurrent NHL, and necropsy specimens from the bone marrow, liver, and kidney revealed no neoplastic infiltration.
  • Bone marrow necropsy showed marked hypocellularity with active histiocytic hemophagocytosis.
  • HPS may have been induced by infection with methicillin-resistant Staphylococcus aureus rather than by lymphoma-associated HPS.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Histiocytosis, Non-Langerhans-Cell / diagnosis. Histiocytosis, Non-Langerhans-Cell / etiology. Lymphoma, B-Cell / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 1987 Jun;2(1):99-102 [3139115.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Bone Marrow Transplant. 1998 Dec;22(12):1219-22 [9894728.001]
  • [Cites] Bone Marrow Transplant. 1998 Mar;21(6):623-5 [9543068.001]
  • [Cites] Med Pediatr Oncol. 1998 Sep;31(3):131-7 [9722893.001]
  • [Cites] J Hematother. 1992 Winter;1(4):329-41 [1285382.001]
  • [Cites] Br J Haematol. 1993 Jan;83(1):21-7 [7679587.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1991 Fall;13(3):305-9 [1665315.001]
  • [Cites] Immunopharmacology. 1994 May-Jun;27(3):173-9 [8071057.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2918-22 [1954380.001]
  • [Cites] Bone Marrow Transplant. 1998 Feb;21(3):301-3 [9489656.001]
  • [Cites] Bone Marrow Transplant. 1990 Nov;6(5):349-52 [2291998.001]
  • [Cites] Blood. 1995 Dec 15;86(12):4706-7 [8541568.001]
  • [Cites] Int J Hematol. 1997 Apr;65(3):215-26 [9114593.001]
  • [Cites] Br J Haematol. 1994 Jun;87(2):243-50 [7947264.001]
  • (PMID = 11372742.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


53. Ferrucci PF, Vanazzi A, Crosta C, Pruneri G, Grana C, Bartolomei M, Paganelli G, Martinelli G: Efficacy of 90Y ibritumomab-tiuxetan treatment in a case of resistant gastric MALT non-Hodgkin's lymphoma. Ecancermedicalscience; 2008;2:79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of 90Y ibritumomab-tiuxetan treatment in a case of resistant gastric MALT non-Hodgkin's lymphoma.
  • Treatment modalities for resistant/relapsing gastric mucosa associated lymphoid tissue (MALT) non-Hodgkin's lymphoma (NHL) are not yet well standardized.
  • In the past, most patients were treated surgically with a gastrectomy, while, more recently, radiotherapy and systemic approaches (chemotherapy and immunotherapy) have been used with improving results.Here, we report the case of a patient affected by MALT NHL resistant to antibiotics, chemotherapy and immunotherapy, who achieved a durable complete remission after radio-immunotherapy treatment with Zevalin ((90)Y ibritumomab-tiuxetan), administered in a single-standard dose.
  • This observation must be confirmed on a larger series but suggests that radio-immunotherapy may be a valid approach in treating relapsing MALT NHL patients, or those resistant to conventional therapies, so avoiding more aggressive and toxic approaches.

  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22275968.001).
  • [ISSN] 1754-6605
  • [Journal-full-title] Ecancermedicalscience
  • [ISO-abbreviation] Ecancermedicalscience
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3234051
  •  go-up   go-down


54. Raina V, Sharma A, Vora A, Shukla NK, Deo SV, Dawar R: Primary gastrointestinal non Hodgkin's lymphoma chemotherapy alone an effective treatment modality: experience from a single centre in India. Indian J Cancer; 2006 Jan-Mar;43(1):30-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal non Hodgkin's lymphoma chemotherapy alone an effective treatment modality: experience from a single centre in India.
  • BACKGROUND: Gastrointestinal tract (GI) is the most frequently involved extra nodal site in non-Hodgkin's lymphoma (NHL).
  • Surgery, radiotherapy and chemotherapy (CT) have been used mostly in various combinations, but lately chemotherapy alone has emerged as an effective option.
  • The purpose of this study is to evaluate efficacy of CT alone in treatment of primary GI-NHL and to compare the results with combined CT+surgery.
  • SETTING AND DESIGN: Retrospective analysis of case records of GI NHL patients.
  • MATERIALS AND METHODS: Over a 15-year period (1986-2000), 77 new cases of primary GI-NHL were registered at our center.
  • GI-NHL was defined according to standard criteria.
  • All patients received chemotherapy.
  • Endoscopy / CT guided biopsies were performed in 42% (32) of patients for the purpose of diagnosis.
  • Laparotomy was done in 58% (45) of patients to establish a diagnosis or as primary or debulking treatment.
  • Seventy eight percent of tumors were intermediate to high grade, 43% (33) received only CT while 57% (44) received CT+surgery.
  • CONCLUSION: Organ-preservation strategy using chemotherapy alone (CT) can be successfully employed in a significant number of patients with primary GI-NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrointestinal Neoplasms / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Female. Humans. India / epidemiology. Laparotomy. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16763360.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


55. Picozzi VJ, Pohlman BL, Morrison VA, Lawless GD, Lee MW, Kerr RO, Ford JM, Delgado DJ, Fridman M, Carter WB: Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Oncology (Williston Park); 2001 Oct;15(10):1296-306; discussion 1310-1, 1314
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.
  • Records from 653 patients treated between 1991 and 1998 in the Oncology Practice Patterns Study (OPPS) were analyzed to determine contemporary chemotherapy delivery patterns in patients with intermediate-grade non-Hodgkin's lymphoma (NHL).
  • Of the 653 patient records reviewed, 90 (14%) omitted an anthracycline or mitoxantrone (Novantrone) from primary therapy.
  • Of 181 advanced-stage patients with responsive disease, 28 (15%) failed to receive at least six treatment cycles.
  • Overall, 283 (43%) of 653 patients potentially received suboptimal chemotherapy due either to choice of regimen or chemotherapy delivered.
  • Patient age > or = 65 years and cardiac comorbidity appeared to have the greatest influence on a physician's decision regarding chemotherapy administration.
  • Among the 492 patients who received CHOP or CNOP, 235 (48%) experienced a delay or reduction in chemotherapy dose (usually neutropenia-related), 100 (20%) developed mucositis, and 116 (24%) were hospitalized for febrile neutropenia.
  • Growth factor was administered to 261 patients (53%), and its primary prophylactic use was associated with a significant reduction in the incidence of hospitalizations for febrile neutropenia in all patient subgroups receiving appropriate chemotherapeutic dose intensity (P = .02).
  • This assessment of chemotherapy delivery to patients with intermediate-grade NHL showed significant variation from current standards.
  • Further analysis of factors influencing chemotherapy delivery might improve therapeutic outcomes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Growth Substances / therapeutic use. Humans. L-Lactate Dehydrogenase / analysis. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Neutropenia / chemically induced. Prednisolone / administration & dosage. Prednisolone / adverse effects. Prednisone / administration & dosage. Prednisone / adverse effects. Reference Values. Retrospective Studies. Severity of Illness Index. Time Factors. Vincristine / administration & dosage. Vincristine / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11702959.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Growth Substances; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone; CHOP protocol; MCOP protocol
  •  go-up   go-down


56. Steffens M, Beauloye V, Brichard B, Robert A, Alexopoulou O, Vermylen Ch, Maiter D: Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL). Clin Endocrinol (Oxf); 2008 Nov;69(5):819-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL).
  • BACKGROUND: Treatments of acute lymphoblastic leukaemia (ALL) and non-Hodgkin lymphoma (NHL), involving various combinations of chemotherapy (chemo), cranial irradiation (CI) and/or bone marrow transplantation after total body irradiation (BMT/TBI), are often successful but may have several long-term harmful effects.
  • OBJECTIVE: To evaluate late endocrine and metabolic complications in adult survivors of childhood ALL and NHL, in relation with the different therapeutic schemes received.
  • DESIGN: Endocrine and metabolic parameters were determined in 94 patients (48 men, mean age: 24 +/- 5 years) with a former childhood ALL (n = 78) or NHL (n = 16) and subgrouped according to their previous treatment: chemo only (group I; n = 44), chemo + CI (group II; n = 32) and chemo + BMT/TBI (group III; n = 18).
  • RESULTS: Severe GH deficiency (peak < 3.0 ng/ml after glucagon) was observed in 22% and 50% of patients of groups II and III, respectively, while hypothyroidism was mainly observed in group III (56%).
  • Moreover, 83% of men developed hypogonadism after BMT/TBI, compared to 17% and 8% in groups I and II, respectively (P < 0.05), and all grafted women had ovarian failure, in contrast with other female patients in whom menarche had occurred spontaneously.
  • CONCLUSIONS: This study reveals a high prevalence of endocrine and metabolic disorders in young adult survivors of childhood ALL or NHL, this frequency mainly depending on the treatment received.
  • Treatment with BMT/TBI is the most detrimental and many of these patients will develop GHD, hypothyroidism, hypogonadism, insulin resistance and dyslipidaemia.
  • [MeSH-major] Endocrine System Diseases / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Metabolic Diseases / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Survivors / statistics & numerical data


57. Osorio S, de la Cámara R, Golbano N, Marti E, Fedele CG, Nieto S, Manzanares R, Fernández-Rañada JM: Progressive multifocal leukoencephalopathy after stem cell transplantation, unsuccessfully treated with cidofovir. Bone Marrow Transplant; 2002 Dec;30(12):963-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive multifocal leukoencephalopathy after stem cell transplantation, unsuccessfully treated with cidofovir.
  • We report a patient with progressive multifocal leukoencephalopathy (PML) after autologous stem cell transplantation (SCT) for non-Hodgkin's lymphoma (NHL).
  • This is the first case of PML after SCT treated with cidofovir, and the fifth case treated with this drug in a patient without human immunodeficiency virus (HIV) infection.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Cytosine / therapeutic use. Leukoencephalopathy, Progressive Multifocal / drug therapy. Organophosphonates. Organophosphorus Compounds / therapeutic use. Peripheral Blood Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain / virology. Combined Modality Therapy. Fatal Outcome. HIV Seronegativity. Humans. Immunocompromised Host. JC Virus / isolation & purification. Lymphoma, Mantle-Cell / complications. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / therapy. Magnetic Resonance Imaging. Male. Middle Aged. Transplantation, Autologous / adverse effects. Treatment Failure

  • Genetic Alliance. consumer health - Progressive multifocal leukoencephalopathy.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12476291.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  • [Number-of-references] 20
  •  go-up   go-down


58. Delaloye AB, Antonescu C, Louton T, Kuhlmann J, Hagenbeek A: Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial. J Nucl Med; 2009 Nov;50(11):1837-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.
  • The objective of this analysis was to assess the radiation exposure associated with (90)Y-ibritumomab tiuxetan when used as consolidation therapy in adults with low or minimal tumor burden after first-line therapy of advanced follicular lymphoma (FL).
  • METHODS: The patients who were enrolled in the phase 3 first-line indolent trial were 18 y or older, with CD20(+) grade 1 or 2 stage III or IV FL, and a partial response, complete response, or unconfirmed complete response to first-line chemotherapy.
  • The patients were allocated randomly to receive a single infusion of unlabeled rituximab 250 mg/m(2) on day -7 and consolidation on day 0 with a single dose of (90)Y-ibritumomab tiuxetan, 14.8 MBq/kg, immediately after unlabeled rituximab, 250 mg/m(2), or no further treatment.
  • Radiation absorbed doses did not differ significantly between patients who had a partial response or complete response to initial therapy.
  • CONCLUSION: In patients with low or minimal residual tumor burden after first-line chemotherapy of advanced FL, whole-body and bone marrow exposure after (90)Y-ibritumomab tiuxetan consolidation showed a significant positive correlation with progression-free survival, whereas dosimetric data could not predict hematologic toxicity.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Internationality. Lymphoma, Follicular / pathology. Lymphoma, Follicular / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Adult. Aged. Environmental Exposure / adverse effects. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiation Dosage. Radiometry. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19837764.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / ibritumomab tiuxetan
  •  go-up   go-down


59. Cohen AM, Grinblat B, Bessler H, Kristt D, Kremer A, Schwartz A, Halperin M, Shalom S, Merkel D, Don J: Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma; 2004 May;45(5):951-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma.
  • The aim of this study was to investigate whether the human Pim-2 (hPim-2) expression is altered in chronic lymphocytic leukemia (B-CLL) and non-Hodgkin's lymphomas (NHL).
  • We analyzed hPim-2 expression in 48 patients with NHL and CLL by quantitative in-situ hybridization, quantitative RT-PCR and FACS analysis.
  • In-situ hybridization revealed a 5.5 +/- 2.2 times higher expression of hPim-2 in NHL over normal lymphocytes (P < 0.001).
  • Similarly, with quantitative RT-PCR, expression in NHL was 1.5 to 2.6 times higher in involved splenic foci compared to nearby uninvolved regions (n = 3).
  • The increased hPim-2 levels correlated with lymphocyte doubling time (DT), in that mRNA levels were two times greater in patients with rapid DT (P < 0.006).
  • Therefore, this report provides direct evidence for a linkage of hPim-2 upregulation to NHL and CLL in man.
  • This relationship between hPim-2 and NHL and CLL raises a number of novel mechanistic options for the genesis and/or progression of some types of human lymphomas.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, Non-Hodgkin / genetics. Protein-Serine-Threonine Kinases / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Humans. In Situ Hybridization. Lymph Nodes / pathology. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation


60. Adachi S, Leoni LM, Carson DA, Nakahata T: Apoptosis induced by molecular targeting therapy in hematological malignancies. Acta Haematol; 2004;111(1-2):107-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis induced by molecular targeting therapy in hematological malignancies.
  • Molecular targeting therapies for hematological malignant diseases such as monoclonal antibodies and small molecules have been reviewed.
  • Imatinib mesylate (STI571) targets the tyrosine kinase activity of the BCR-ABL fusion protein in CML, and was superior to IFN-alpha plus low-dose cytarabine in newly diagnosed chronic-phase CML in a phase III randomized study.
  • Combination therapies with imatinib and new strategies for downregulation of intracellular BCR-ABL protein levels have also been investigated from the phenomenon of resistance to imatinib.
  • Anti-CD20 (rituximab) became the first monoclonal antibody approved for the treatment of a relapsed/refractory follicular/low-grade NHL and promising results were obtained from a phase III randomized study.
  • Although antibody-dependent cell-mediated cytotoxicity and complement-mediated cytotoxicity are likely to be the major effectors of B-cell depletion in vivo, direct cytotoxicity by CD20 monoclonal antibody on B-cell lines in vitro has been reported.
  • Finally we show our promising in vitro and in vivo data of R-etodolac (a non-steroidal anti-inflammatory drug lacking cyclooxygenase inhibitor activity) against chronic lymphocytic leukemia (CLL) cells.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Hematologic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 S. Karger AG, Basel
  • (PMID = 14646349.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents
  • [Number-of-references] 141
  •  go-up   go-down


61. Zinzani PL: Salvage chemotherapy in follicular non-Hodgkin's lymphoma: focus on tolerability. Clin Lymphoma Myeloma; 2006 Sep;7(2):115-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy in follicular non-Hodgkin's lymphoma: focus on tolerability.
  • Follicular lymphoma (FL) is typically characterized by repeated remissions and relapses, and many patients receive a number of therapeutic interventions during their disease course.
  • Although treatment options are evolving rapidly, stem cell transplantation offers a potentially favorable impact on survival.
  • In general, many patients with FL are not eligible for this approach by virtue of age and/or comorbid disease.
  • Salvage chemotherapy consequently remains the mainstay of treatment, being individualized according to disease and patient characteristics, goals of therapy, and patient preference.
  • Many of the cytotoxic agents used in relapsed FL are highly myelotoxic, leading to significant morbidity and mortality, including febrile neutropenia, hemorrhage, and impaired quality of life.
  • Acute myeloid leukemias, myelodysplastic syndromes, or solid tumors can occur after chemotherapy with alkylating agents.
  • The cardiotoxic profile of anthracycline antibiotics is well recognized, and several agents, including carmustine and cyclophosphamide, can cause lung injury.
  • Persistent neurotoxicity, nephrotoxicity, ototoxicity, and vascular toxicity have also been reported in association with chemotherapeutic agents used in patients with relapsed FL.
  • Novel therapeutic strategies might allow patients to achieve longer remissions, potentially reducing lifetime exposure to repeated cycles of chemotherapy and their attendant toxicities.
  • These could include the use of more efficient preparative and purging approaches in the transplantation setting or the administration of rituximab maintenance therapy after (immuno) chemotherapy induction or transplantation.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Lymphoma, Follicular / complications. Lymphoma, Follicular / therapy. Salvage Therapy
  • [MeSH-minor] Age Factors. Comorbidity. Disease-Free Survival. Humans. Remission Induction. Stem Cell Transplantation / methods. Time Factors

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17026822.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 94
  •  go-up   go-down


62. Re D, Schwenk A, Hegener P, Bamborschke S, Diehl V, Tesch H: Guillain-Barré syndrome in a patient with non-Hodgkin's lymphoma. Ann Oncol; 2000 Feb;11(2):217-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guillain-Barré syndrome in a patient with non-Hodgkin's lymphoma.
  • We describe a case of Guillain-Barré syndrome (GBS) in a patient with non-Hodgkin's lymphoma (NHL).
  • A 21-year-old woman with a newly diagnosed stage IV high-grade lymphoma (precursor T-cell NHL according to the R.E.A.L.
  • Classification) developed flaccid quadriparesis and bilateral facial diplegia after three weeks of treatment with vincristine, daunorubicin, L-asparaginase and prednisolone.
  • Despite treatment with intravenous immunoglobulins her neurological symptoms progressed.
  • After partial remission of neurologic symptoms, induction chemotherapy with cyclophosphamide and cytarabine was continued without any further complication.
  • Three months later, the lymphoma was in complete remission.
  • GBS has been described in Hodgkin's disease and after bone marrow transplantation but is rare in NHL.
  • In patients with NHL who develop neurological symptoms, drug toxicity and nervous system infiltration are the leading cause of neuropathology, but GBS should be considered in the differential diagnosis.

  • Genetic Alliance. consumer health - Guillain-Barre Syndrome.
  • MedlinePlus Health Information. consumer health - Guillain-Barre Syndrome.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10761759.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous; 5J49Q6B70F / Vincristine; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


63. Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, Ries LA, Fraumeni JF Jr: Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol; 2010 Nov 20;28(33):4935-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.
  • PURPOSE: Previous studies have shown increased risks of second malignancies after non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL); however, no earlier investigation has quantified differences in risk of new malignancy by lymphoma subtype.
  • PATIENTS AND METHODS: We evaluated second cancer and leukemia risks among 43,145 1-year survivors of CLL/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), or follicular lymphoma (FL) from 11 Surveillance, Epidemiology, and End Results (SEER) population-based registries during 1992 to 2006.
  • RESULTS: Among patients without HIV/AIDS-related lymphoma, lung cancer risks were significantly elevated after CLL/SLL and FL but not after DLBCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL = 1.28, DLBCL = 1.00; Poisson regression P for difference among subtypes, P(Diff) = .001).
  • A similar pattern was observed for risk of cutaneous melanoma (SIR: CLL/SLL = 1.92, FL = 1.60, DLBCL = 1.06; P(Diff) = .004).
  • Acute nonlymphocytic leukemia risks were significantly elevated after FL and DLBCL, particularly among patients receiving initial chemotherapy, but not after CLL/SLL (SIR: CLL/SLL = 1.13, FL = 5.96, DLBCL = 4.96; P(Diff) < .001).
  • Patients with HIV/AIDS-related lymphoma (n = 932) were predominantly diagnosed with DLBCL and had significantly and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 138.90).
  • CONCLUSION: Our findings suggest that differing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities, and other risk factors (eg, viral infections, tobacco use) among lymphoma subtypes contribute to the patterns of second malignancy risk.
  • Elucidating these patterns may provide etiologic clues to lymphoma as well as to the second malignancies.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):159-66 [15970927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6 [16214923.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):419-20 [16125820.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):108-15 [16708354.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1481-8 [17043014.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2314-20 [17107903.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]
  • [Cites] Cancer Causes Control. 2007 Mar;18(2):135-42 [17235495.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):151-6 [17351903.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4617-26 [17311989.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):43-50 [17906957.001]
  • [Cites] Haematologica. 2008 Mar;93(3):398-404 [18268277.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1850-7 [18347006.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):605-15 [18402527.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Expert Opin Pharmacother. 2008 Jun;9(9):1481-94 [18518779.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix [18954744.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1175-83 [18971419.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):874-80 [11241258.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1610-8 [11250989.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):182-92 [11830608.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3878-84 [12228208.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):74-8 [12556962.001]
  • [Cites] Med Oncol. 2003;20(3):211-20 [14514970.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):383-9 [14746857.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1222-8 [14576060.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1083-91 [15247562.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):565-71 [8636772.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):216-28 [15578683.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):248-55 [19211444.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):873-5 [19620980.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4573-5 [15741224.001]
  • (PMID = 20940199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3020697
  •  go-up   go-down


64. Zinzani PL, Tani M, Stefoni V, Albertini P, Bendandi M, Gherlinzoni F, Alinari L, Vigna E, Tura S: Efficacy of vinorelbine, epirubicin and prednisone combination regimen in pretreated elderly patients with aggressive non-Hodgkin's lymphoma. Haematologica; 2001 Mar;86(3):287-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of vinorelbine, epirubicin and prednisone combination regimen in pretreated elderly patients with aggressive non-Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVES: To assess the efficacy and toxic profile of the NAEPP protocol, a regimen including vinorelbine, epirubicin and prednisone, in a particularly troublesome subset of patients: pretreated elderly patients with aggressive non-Hodgkin's lymphoma (NHL).
  • DESIGN AND METHODS: From November 1998 to January 2000, 20 pretreated patients who had all relapsed after first-line VNCOP-B chemotherapy were enrolled in a phase II trial and treated with the NAEPP regimen: vinorelbine (25 mg/m(2) i.v. on days 1 and 8), epirubicin (40 mg/m(2) i.v. on days 1 and 8), and prednisone (40 mg/m(2) on days 1 and 8) with granulocyte colony-stimulating factor administered at 5 mg/kg/day on days 2-5 and days 9-12.
  • Chemotherapy was repeated every 4 weeks for a total of 6 cycles.
  • The response rate was not affected either by type of relapse presentation (nodal versus nodal plus extranodal), presence of bulky disease, or time of relapse.
  • INTERPRETATION AND CONCLUSIONS: These preliminary data suggest that the NAEPP regimen is an effective combination with a low toxicity profile in elderly pretreated patients with aggressive NHL.
  • Further trials using NAEPP as a consolidation phase following first-line treatment are needed to establish the advantage in terms of CR rate and relapse-free survival in these patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Epirubicin / administration & dosage. Epirubicin / standards. Epirubicin / toxicity. Female. Humans. Male. Prednisone / administration & dosage. Prednisone / standards. Prednisone / toxicity. Therapeutic Equivalency. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives. Vinblastine / standards. Vinblastine / toxicity

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11255276.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine; VB0R961HZT / Prednisone
  •  go-up   go-down


65. Robak T, Góra-Tybor J, Lech-Marańda E, Błoński JZ, Kasznicki M: Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. Eur J Haematol; 2001 Mar;66(3):188-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
  • The aim of our study was to determine the effectiveness and toxicity of combined chemotherapy consisting of cladribine (2-chloro-deoxyadenosine, 2-CdA), mitoxantrone and cyclophosphamide (CMC regimen) in the treatment of refractory or relapsed indolent lymphoproliferative disorders.
  • The treatment course consisted of 2-CdA given at a dose of 0.12 mg/kg/24 h in a 2-h intravenous infusion for 5 (CMC5) or 3 (CMC3) consecutive days, mitoxantrone 10 mg/m2 on day 1 and cyclophosphamide 650 mg/m2/iv on day 1.
  • Thirty-three patients (19 with B-CLL and 14 with LG-NHL) entered the study and all of them were eligible.
  • Twenty patients (60.6%) were recurrent after prior therapy and 13 (39.4%) had refractory disease.
  • All patients received 5 or more cycles of chemotherapy before CMC treatment.
  • One patient with B-CLL and three patients with lymphocytic lymphoma achieved CR (12.1%).
  • Among 12 patients (36.4%) who achieved PR there were 6 CLL patients, and 6 lymphoma patients.
  • Severe neutropenia was seen in 11/33 (33.3%) patients, more frequently in patients who received CMC5 than in the patients who received CMC3, both in the CLL (50.0% and 28.5%, respectively) and in the LG-NHL group (22.2% and 0%, respectively).
  • Infections and fever of unknown origin complicated the treatment with CMC5 more often than with CMC3: five episodes were seen in 3 patients treated with CMC3 when compared to 15 episodes in 12 patients treated with CMC5.
  • In conclusion, the CMC programme is an active combined regimen in heavily pre-treated CLL and LG-NHL patients.
  • However, its toxicity is significant and we suggest a shortening of 2-CdA infusion from 5 to 3 d in further studies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Aged. Bone Marrow Diseases / chemically induced. Cladribine / administration & dosage. Cladribine / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Remission Induction. Salvage Therapy. Treatment Outcome

  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11350487.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 47M74X9YT5 / Cladribine; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; CMC protocol 2
  •  go-up   go-down


66. De Giacomo T, Venuta F, Anile M, Diso D, Rolla M, Coloni GF: Non-Hodgkin's lymphoma, presenting as an isolated endobronchial mass after bilateral lung transplantation: a case report. Transplant Proc; 2007 Dec;39(10):3541-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma, presenting as an isolated endobronchial mass after bilateral lung transplantation: a case report.
  • BACKGROUND: Lymphoma is a serious complication following solid organ transplantation.
  • Endobronchial involvement of non-Hodgkin's lymphoma (NHL) is rare usually occurring in the setting of widely disseminated disease.
  • Only a few cases of isolated endobronchial NHL have been reported.
  • METHODS: Herein we have described a case of an obstructive endobronchial NHL lesion in a young patient, which developed 6 years after bilateral lung transplantation for cystic fibrosis.
  • RESULTS: Successful treatment was obtained with endoscopic resection of the lesion followed by chemotherapy.
  • CONCLUSIONS: In rare cases NHL may present as an isolated endobronchial mass in the main bronchi.
  • Because in these cases the prognosis seems to be better, early diagnosis is essential.
  • Rigid bronchoscopy offers the opportunity to safely obtain large amounts of tissue for complete histological diagnosis and to de-obstruct the airway to relieve the symptoms.
  • [MeSH-major] Bronchial Neoplasms / radiography. Lung Transplantation / adverse effects. Lymphoma, Non-Hodgkin / radiography
  • [MeSH-minor] Adult. Bronchi / pathology. Female. Humans. Radiography, Thoracic. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089433.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Robak T, Robak P, Smolewski P: TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs; 2009 Dec;10(12):1383-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies.
  • TRU-016, under development by Trubion Pharmaceuticals Inc and Facet Biotech Corp, is an intravenously administered anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), as well as for autoimmune and inflammatory diseases.
  • TRU-016 was created by humanizing SMIP-016, a mouse/human chimeric protein that demonstrated antitumor activity against lymphoid malignancies in preclinical studies, including in human B-cell tumor mouse xenograft models.
  • In addition, TRU-016 demonstrated synergistic or additive activity in NHL cells in combination with rituximab, rapamycin, doxorubicin and bendamustine.
  • In a phase I/II clinical trial in refractory or relapsed patients with CLL or small lymphocytic lymphoma, TRU-016 was well tolerated, with clinical benefit and a reduced absolute lymphocyte count observed in all cohorts dosed at > 0.1 mg/kg.
  • TRU-016 is a promising therapeutic agent for patients with B-cell lymphoid malignancies, especially patients refractory to standard treatment.
  • [MeSH-major] Antigens, CD / immunology. Antigens, Neoplasm / immunology. Antineoplastic Agents / therapeutic use. Immunoglobulin G / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, B-Cell / drug therapy. Recombinant Fusion Proteins / therapeutic use
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Autoimmune Diseases / drug therapy. Autoimmune Diseases / immunology. Clinical Trials as Topic. Drug Evaluation, Preclinical. Humans. Inflammation / drug therapy. Inflammation / immunology. Mice. Tetraspanins

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19943209.001).
  • [ISSN] 2040-3429
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD37 protein, human; 0 / Immunoglobulin G; 0 / Recombinant Fusion Proteins; 0 / TRU 016; 0 / Tetraspanins
  • [Number-of-references] 73
  •  go-up   go-down


68. Ezzat H, Filipenko D, Vickars L, Galbraith P, Li C, Murphy K, Montaner JS, Harris M, Hogg RS, Vercauteren S, Leger CS, Zypchen L, Leitch HA: Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy. HIV Clin Trials; 2007 May-Jun;8(3):132-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy.
  • PURPOSE: Recent trials suggest serious toxicity in HIV-associated non-Hodgkin's lymphoma (NHL) with rituximab (R) and chemotherapy (CT), offsetting the benefit of rituximab.
  • METHOD: We retrospectively reviewed experience with CHOP-R vs. CT in 40 patients with HIV-associated diffuse large B-cell lymphoma (DLBCL) diagnosed between December 1992 and February 2006, all of whom were treated with curative intent.
  • Rituximab-treated patients had a lower death rate from lymphoma (CHOP-R, 2 [16%] vs. CT, 15 [63%]; p < .04), and overall mortality (CHOP-R, 5 [42%] vs. CT, 21 [88%]; p < .01).
  • CONCLUSION: These retrospective data suggest that fatal toxicity of rituximab in HIV-NHL is not increased provided HAART is used, that the addition of rituximab to CT improved outcome, and that further prospective trials investigating this issue are warranted.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / complications. HIV Infections / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Retrospective Studies. Rituximab. Survival Analysis. Treatment Outcome


69. Hsu CH, Sun SS, Kao CH, Lin CC, Lee CC: Differentiation of low-grade gastric MALT lymphoma and high-grade gastric MALT lymphoma: the clinical value of Ga-67 citrate scintigraphy--a pilot study. Cancer Invest; 2002;20(7-8):939-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of low-grade gastric MALT lymphoma and high-grade gastric MALT lymphoma: the clinical value of Ga-67 citrate scintigraphy--a pilot study.
  • Ga-67 citrate scintigraphy has been routinely and extensively used to evaluate non-Hodgkin's lymphoma (NHL) for more than 20 years.
  • Gastric lymphoma of mucosa-associated lymphoid tissue (MALT) is by far the most common extranodal primary NHL.
  • Gastric MALT lymphoma can be classified as low-grade (LG) or high-grade (HG).
  • Low-grade gastric MALT lymphoma can be cured by eradication of Helicobacter pylori; but radiotherapy and/or chemotherapy and/or surgery are the major methods of treatment for the HG gastric MALT lymphoma.
  • The purpose of this study was to determine whether Ga-67 citrate scintigraphy can distinguish the LG gastric MALT lymphoma from the HG gastric MALT lymphoma.
  • Twenty-one patients (11 men and 10 women ranging in age from 38 to 83 years) with histologically confirmed gastric MALT lymphoma were enrolled.
  • All 21 patients underwent Ga-67 citrate scintigraphy before treatment.
  • Among the three patients who had positive results in the LG group, the uptake of gastric MALT lymphoma was lower than that of the liver.
  • The Ga-67 citrate scintigraphy is of good clinical value for the differentiation of the LG gastric MALT lymphoma and the HG gastric MALT lymphoma.
  • We think that the major value of Ga-67 citrate scintigraphy will be in following the patients with HG gastric MALT lymphoma after treatment to assess response of therapy and to detect possible recurrence and perhaps in determining transformation from the LG to HG gastric MALT lymphoma.
  • However, further investigation is needed to understand the relationship between the uptake of Ga-67 citrate in gastric MALT lymphoma and transformation.
  • [MeSH-major] Citrates. Gallium. Lymphoma, B-Cell, Marginal Zone / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Radiopharmaceuticals. Stomach Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Gallium Radioisotopes. Gastric Mucosa / pathology. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. GALLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12449725.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Citrates; 0 / Gallium Radioisotopes; 0 / Radiopharmaceuticals; 27905-02-8 / gallium citrate; CH46OC8YV4 / Gallium
  •  go-up   go-down


70. Faber AC, Chiles TC: Resveratrol induces apoptosis in transformed follicular lymphoma OCI-LY8 cells: evidence for a novel mechanism involving inhibition of BCL6 signaling. Int J Oncol; 2006 Dec;29(6):1561-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resveratrol induces apoptosis in transformed follicular lymphoma OCI-LY8 cells: evidence for a novel mechanism involving inhibition of BCL6 signaling.
  • BCL6, a transcriptional repressor frequently translocated in lymphomas, including diffuse large B-cell lymphoma (DLBCL) and transformed follicular lymphoma (FL), regulates germinal center B-cell differentiation.
  • We report herein that resveratrol treatment of human LY8 follicular lymphoma cells leads to an accumulation of LY8 cell in G0/G1 phase and apoptosis.
  • These results demonstrate for the first time that resveratrol inhibits a BCL6-linked pathway and suggest that loss of BCL6 expression may represent a key event underlying the anti-proliferative activities of resveratrol on LY8 cells.
  • The use of resveratrol to treat aggressive lymphomas with BCL6 and/or MYC translocations may prove useful as an effective therapy.
  • [MeSH-major] Apoptosis / drug effects. DNA-Binding Proteins / antagonists & inhibitors. Lymphoma, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy. Stilbenes / pharmacology
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. Cell Cycle / drug effects. Cell Line, Transformed. Genes, myc / drug effects. Genes, p53 / drug effects. Humans. MAP Kinase Signaling System / drug effects. Mitogen-Activated Protein Kinase Kinases / genetics. Mitogen-Activated Protein Kinase Kinases / metabolism. Proliferating Cell Nuclear Antigen / genetics

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RESVERATROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17088997.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI-49994
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Proliferating Cell Nuclear Antigen; 0 / Stilbenes; 0 / p27 antigen; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; Q369O8926L / resveratrol
  •  go-up   go-down


71. Baldo P, Rupolo M, Compagnoni A, Lazzarini R, Bearz A, Cannizzaro R, Spazzapan S, Truccolo I, Moja L: Interferon-alpha for maintenance of follicular lymphoma. Cochrane Database Syst Rev; 2010;(1):CD004629
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-alpha for maintenance of follicular lymphoma.
  • BACKGROUND: Indolent non-Hodgkin's lymphoma, in particular follicular lymphoma (FL), is characterized by multiple remissions and relapses.
  • Several studies have used interferon-alpha (IFN) to control this disease, both as induction and as maintenance therapy.
  • It is not yet clear whether IFN can be associated with a survival benefit although it may prolong progression-free survival.
  • OBJECTIVES: To determine the effects of IFN in the maintenance therapy of FL.
  • SELECTION CRITERIA: Randomised controlled trials of IFN versus no intervention or placebo, or IFN plus chemotherapy versus chemotherapy alone, in a maintenance setting in patients with non-Hodgkin's FL.
  • The drug was IFN alfa-2b in six trials and alfa-2a in two.
  • Trials were heterogeneous in terms of diagnosis of FL, using several classification systems.
  • IFN had been compared with placebo/no intervention in five trials and other chemotherapy in three.
  • The effect of IFN was similar to that of placebo on overall survival (hazard ratio (HR) 0.90, 95% CI 0.61 to 1.34) whereas IFN was more effective when added to chemotherapy (HR 0.68, 95% confidence interval (CI) 0.52 to 0.90).
  • AUTHORS' CONCLUSIONS: There is evidence that addition of IFN as maintenance therapy for FL improves progression-free survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Lymphoma, Follicular / drug therapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20091564.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; 99210-65-8 / interferon alfa-2b
  • [Number-of-references] 79
  •  go-up   go-down


72. Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, Scadden D, Kaplan L, Ambinder R, Levine A, Harrington W, Grochow L, Flexner C, Tan B, Straus D, AIDS Malignancy Consortium: Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol; 2001 Apr 15;19(8):2171-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
  • PURPOSE: This study investigated the efficacy, toxicity, and pharmacokinetic interactions resulting from simultaneous combination chemotherapy and highly active antiretroviral therapy (HAART) for patients with human immunodeficiency virus (HIV)-associated non-Hodgkin's lymphoma (NHL).
  • In addition, the effects on viral load, CD4 counts, and opportunistic infections were examined with the use of combination chemotherapy combined with HAART.
  • PATIENTS AND METHODS: Sixty-five patients with previously untreated and measurable disease at any stage of HIV-associated NHL of intermediate or high grade were entered onto this study at 17 different centers.
  • Grade 3 or 4 neutropenia occurred in 25% of patients receiving mCHOP and 12% of those receiving full-dose CHOP combined with G-CSF (25% v 12%).
  • There were similar numbers of patients with grade 3 or 4 hyperbilirubinemia (12% and 17%), constipation and abdominal pain (18% and 17%), and transaminase elevation (48% and 52%) on the modified and full-dose arms of the study, respectively.
  • Human immunodeficiency virus (HIV) load declined from a median baseline value of 29,000 copies/mL to a median minimum value on therapy of 500 copies/mL.
  • CONCLUSION: Either modified-dose or full-dose CHOP chemotherapy for HIV-NHL, delivered with HAART, is effective and tolerable.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV Infections / complications. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Indinavir / administration & dosage. Lamivudine / administration & dosage. Male. Middle Aged. Neutropenia / chemically induced. Prednisone / administration & dosage. Stavudine / administration & dosage. Treatment Outcome. Vincristine / administration & dosage. Viral Load

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Non-ARV Adverse Events .
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • Hazardous Substances Data Bank. INDINAVIR SULFATE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. STAVUDINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11304769.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA 70054; United States / NCI NIH HHS / CA / U01 CA 70072; United States / NCI NIH HHS / CA / U01 CA70019; United States / NCI NIH HHS / CA / U01 CA70047; United States / NCI NIH HHS / CA / U01 CA70058; United States / NCI NIH HHS / CA / U01 CA70062; United States / NCI NIH HHS / CA / U01 CA7007; United States / NCI NIH HHS / CA / U01 CA70078; United States / NCI NIH HHS / CA / U01 CA70080; United States / NCI NIH HHS / CA / U01 CA70081; United States / NCI NIH HHS / CA / U01 CA71375
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 2T8Q726O95 / Lamivudine; 5J49Q6B70F / Vincristine; 5W6YA9PKKH / Indinavir; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BO9LE4QFZF / Stavudine; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


73. Hitchcock S, Ng AK, Fisher DC, Silver B, Bernardo MP, Dorfman DM, Mauch PM: Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2002 Mar 15;52(4):1058-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma.
  • PURPOSE: To evaluate the treatment outcome in patients with mucosa-associated lymphoid tissue (MALT)/marginal zone (MZ) non-Hodgkin's lymphoma (NHL).
  • MATERIALS AND METHODS: Between 1986 and 2000, 66 patients with clinical stage (CS) I-IV MALT/MZ NHL were treated; these comprise the study population.
  • Forty-five patients (68%) had CS I-II and 21 (32%) had CS III-IV disease.
  • Twenty-nine of the 45 CS I-II patients received radiation therapy (RT) alone, and 6 patients had surgery and RT.
  • The median RT dose was 3350 cGy.
  • Among the 21 CS III-IV patients, treatment included chemotherapy alone (15), chemotherapy + RT (3), surgery (1), surgery + chemotherapy (1), and RT alone (1).
  • RESULTS: All 35 early-stage and all 4 advanced-stage patients who received RT as part of initial treatment achieved local control.
  • The 5-year OS was 93% and PFS was 75% among CS I-II patients; the corresponding estimates in CS III-IV patients were 83% and 14%, respectively.
  • CONCLUSION: Modest doses of RT provide excellent local control in patients with MALT/MZ NHL.
  • The poor PFS in advanced-stage patients suggests the need to develop alternative systemic treatment strategies for this disease.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Conjunctival Neoplasms / mortality. Conjunctival Neoplasms / pathology. Conjunctival Neoplasms / radiotherapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Orbital Neoplasms / mortality. Orbital Neoplasms / pathology. Orbital Neoplasms / radiotherapy. Parotid Neoplasms / mortality. Parotid Neoplasms / pathology. Parotid Neoplasms / radiotherapy. Recurrence. Stomach Neoplasms / pathology. Stomach Neoplasms / radiotherapy. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11958902.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


74. Nishiuchi T, Imachi H, Fujiwara M, Murao K, Onishi H, Kiguchi T, Takimoto H, Kushida Y, Haba R, Ishida T: A case of non-Hodgkin's lymphoma primary arising in both adrenal glands associated with adrenal failure. Endocrine; 2009 Feb;35(1):34-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of non-Hodgkin's lymphoma primary arising in both adrenal glands associated with adrenal failure.
  • It is known that adrenal insufficiency is one of the complications in primary adrenal lymphoma, especially those with bilateral adrenal involvement.
  • He was diagnosed as having non-Hodgkin's lymphoma (NHL) with primaries arising in both adrenal glands.
  • Primary adrenal lymphoma (PAL) is a rare extra-nodal NHL.
  • Although an appropriate treatment of this disease has not been established, our case has demonstrated that the combination of rituximab and THP-COP chemotherapy could be administered, and that it improved clinical manifestations.
  • This case raises the suggestion that malignant lymphoma should be suspected in patients with bilateral adrenal tumors that present with progressive adrenal insufficiency.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Insufficiency / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Neoplasms, Multiple Primary / diagnosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Intern Med. 2003 Jul;42(7):609-14 [12879956.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):460-3 [14730391.001]
  • [Cites] Int J Hematol. 2005 Apr;81(3):246-54 [15814336.001]
  • [Cites] Rev Esp Enferm Dig. 2007 Aug;99(8):471-4 [18020866.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jan;56(1):95-101 [11849252.001]
  • [Cites] Postgrad Med J. 1985 Jul;61(717):637-9 [4022898.001]
  • [Cites] Clin Nucl Med. 2005 Apr;30(4):222-30 [15764875.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Medicine (Baltimore). 1961 Feb;40:31-84 [13743408.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • (PMID = 19002613.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Ogami A, Morimoto A, Hibi S, Todo S, Sugimoto T, Mori K, Imamura T, Ishida H, Yoshihara T, Iguchi A, Imaizumi M, Imashuku S: Secondary acute promyelocytic leukemia following chemotherapy for non-Hodgkin's lymphoma in a child. J Pediatr Hematol Oncol; 2004 Jul;26(7):427-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary acute promyelocytic leukemia following chemotherapy for non-Hodgkin's lymphoma in a child.
  • Of the several kinds of therapy-related leukemia, therapy-related acute promyelocytic leukemia (t-APL) is most closely associated with topoisomerase II inhibitor administration for treatment of malignancies in adults.
  • Although rare in children, the majority of therapy-related malignancies have been etoposide-related APL associated with Langerhans cell histiocytosis.
  • The authors describe the development of t-APL after chemotherapy administered for non-Hodgkin's lymphoma (NHL) in an 8-year-old girl.
  • One month after cessation of the 3-year chemotherapy regimen of doxorubicin and other agents but not etoposide or radiotherapy, the patient was diagnosed with t-APL with positive PML-RARA molecular abnormality.
  • The patient attained a complete remission following treatment with all-trans retinoic acid-containing chemotherapy.
  • Thereafter, she successfully received hematopoietic stem cell transplantation from an HLA-matched sibling donor.
  • Development of t-APL associated with NHL in children appears to be rare.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Promyelocytic, Acute / pathology. Lymphoma, Non-Hodgkin / pathology. Neoplasms, Second Primary / pathology

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15218416.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


76. Shikama N, Ikeda H, Nakamura S, Oguchi M, Isobe K, Hirota S, Hasegawa M, Nakamura K, Sasai K, Hayabuchi N: Localized aggressive non-Hodgkin's lymphoma of the nasal cavity: a survey by the Japan Lymphoma Radiation Therapy Group. Int J Radiat Oncol Biol Phys; 2001 Dec 1;51(5):1228-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized aggressive non-Hodgkin's lymphoma of the nasal cavity: a survey by the Japan Lymphoma Radiation Therapy Group.
  • PURPOSE: To clarify the role of radiotherapy and chemotherapy in the treatment of patients with localized aggressive non-Hodgkin's lymphomas (NHL) originating in the nasal cavity.
  • METHODS AND MATERIALS: The survey, administered at 25 Japanese institutes in 1998, enabled us to collect the clinical data for 787 patients with localized aggressive NHL who were treated between 1988 and 1992.
  • RESULTS: There were 42 patients (5%) with nasal lymphomas.
  • Twelve of these patients received radiotherapy alone, and 30 were treated with a combination of radiotherapy and chemotherapy.
  • The median radiation dose was 47 Gy (22-66).
  • Twelve patients were reviewed histopathologically according to REAL (Revised European-American Classification of Lymphoid neoplasms) classification.
  • T-cell or natural killer (NK) cell lymphomas were detected in 9 patients (75%), and diffuse large B-cell lymphomas in 3 (25%).
  • The 5-year DFS rate for the 30 patients treated with the combined therapy was 64% and that for the 12 patients treated with radiotherapy alone was 46% (p = 0.021).
  • For the 34 patients with stage-modified International Prognostic Index (m-IPI) 0-1, the 5-year DFS rates of those treated with the combined therapy and radiotherapy alone were 68% and 45%, respectively (p = 0.020), but there was no difference in DFS rate among the two groups of patients with m-IPI 2-3.
  • The 5-year local control rates of the patients who received >46 Gy (n = 22) and < or =46 Gy (n = 20) were 95% and 76% (p = 0.087), respectively.
  • There was no significant difference among the 5-year DFS rates (62% vs. 67%) and local control rates (87% vs. 100%) of the patients with T-cell or NK-cell lymphoma and diffuse large B-cell lymphoma.
  • CONCLUSIONS: Patients with nasal lymphomas (m-IPI 0-1) should be treated with combined therapy.
  • For the patients with high risk (m-IPI 2-3), the effectiveness of combined therapy was not clarified because of the small number of the patients.
  • A high radiation dose >46 Gy may need to be used to achieve good local control.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Nose Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11728681.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Zinzani PL, Gandolfi L, Stefoni V, Fanti S, Fina M, Pellegrini C, Montini GC, Derenzini E, Broccoli A, Argnani L, Pileri S, Baccarani M: Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. Clin Lymphoma Myeloma Leuk; 2010 Aug;10(4):258-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome.
  • BACKGROUND: Based on historical data on the role of radioimmunotherapy (RIT) in pretreated non-Hodgkin lymphoma, we reviewed our hospital's clinical database.
  • PATIENTS AND METHODS: Between 2005 and 2008, 57 patients previously treated with at least 1 rituximab-containing chemotherapy were treated with Yttrium-90-labeled ibritumomab tiuxetan ((90)Y-IT).
  • A total of 46 patients had stage III/IV disease (31 with bone marrow involvement); 6 had bulky disease.
  • According to histology, 53 were follicular lymphoma (FL), 2 were marginal zone lymphoma, and 2 were small lymphocytic lymphoma.
  • Twenty-six of 40 patients (65%) who obtained a CR are in continuous CR (CCR) with a median follow-up of 20 months (range, 10-42 months); 4 of them still maintain their CCR after 36 months.
  • All patients achieving a CCR had FL, and 21 of them with stage III/IV disease; 12 of 26 had been heavily pretreated (>or= 3 previous treatments), and 2 had had autologous stem cell transplantation.
  • Toxicity was primarily hematologic and mostly transient; no grade 4 extrahematologic toxicity was observed.
  • CONCLUSION: This study confirms the safety and high efficacy of (90)Y-IT RIT in heavily pretreated FL patients, with the possibility of having a subset of long-term responders.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Time. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20709661.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


78. Pettengell R, Donatti C, Hoskin P, Poynton C, Kettle PJ, Hancock B, Johnson S, Dyer MJ, Rule S, Walker M, Wild D: The impact of follicular lymphoma on health-related quality of life. Ann Oncol; 2008 Mar;19(3):570-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of follicular lymphoma on health-related quality of life.
  • BACKGROUND: The purpose of this study was to determine whether there was a relationship between disease activity and health functioning, as measured by a range of patient-reported outcome (PRO) measures in patients with follicular lymphoma (FL).
  • PATIENTS AND METHODS: A total of 222 patients with FL were recruited from eight sites across the UK and they completed a number of PRO measures.
  • The relationship between these disease states and their level of health functioning was assessed as well as the relationship between being 'on' or 'off' chemotherapy and disease state.
  • RESULTS: In terms of health-related quality of life (HRQoL), participants in the relapsed category had the lowest mean physical well-being, emotional well-being, functional well-being and social well-being score.
  • CONCLUSION: The results of this study demonstrate that various aspects of patient-reported health outcomes differ according to disease state in patients with FL.
  • [MeSH-major] Anxiety / epidemiology. Depression / epidemiology. Lymphoma, Follicular / classification. Lymphoma, Follicular / epidemiology. Quality of Life
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Comorbidity. Employment / statistics & numerical data. Female. Humans. Male. Middle Aged. Regression Analysis. Treatment Outcome. United Kingdom / epidemiology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Depression.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056649.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


79. Miyazaki K, Masuya M, Yamaguchi M, Isaka S, Nakase K, Kobayashi T, Nakamura S, Shiku H: [Angioimmunoblastic T-cell lymphoma occurring four months after autologous peripheral blood stem cell transplantation with high-dose chemotherapy for follicular lymphoma]. Rinsho Ketsueki; 2005 Sep;46(9):1065-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma occurring four months after autologous peripheral blood stem cell transplantation with high-dose chemotherapy for follicular lymphoma].
  • A 62-year-old Japanese woman was diagnosed as having follicular lymphoma (FL, grade 3, CS IIIA, IPI high-intermediate risk) in May 1998.
  • After eight courses of CHOP therapy, she achieved a complete remission (CR).
  • In November 1998, her FL relapsed, and she achieved a second CR after two courses of MINE therapy.
  • High-dose etoposide was used for autologous peripheral stem cell mobilization.
  • In May 1999, she underwent high-dose chemotherapy with autologous peripheral blood stem cell transplantation (auto-PBSCT).
  • Four months after the auto-PBSCT, bilateral cervical lymphadenopathy developed.
  • Histopathological findings from a biopsied cervical lymph node showed angioimmunoblastic T-cell lymphoma (AILT).
  • The patient was treated with modified CVP therapy, and she is alive with no evidence of lymphoma five years after auto-PBSCT.
  • Clinical and histopathological findings showed that the FL and AILT in this case were not concomitant.
  • It is thought that in this case, the AILT developed as a post-transplant lymphoproliferative disorder after auto-PBSCT for the FL.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Etoposide / adverse effects. Immunoblastic Lymphadenopathy / etiology. Lymphoma, Follicular / therapy. Lymphoma, T-Cell / etiology. Peripheral Blood Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Female. Humans. Middle Aged. Prednisone / administration & dosage. Pulse Therapy, Drug. Time Factors. Transplantation, Autologous. Treatment Outcome. Vincristine / administration & dosage


80. Arcaini L, Merli M, Passamonti F, Bruno R, Brusamolino E, Sacchi P, Rattotti S, Orlandi E, Rumi E, Ferretti V, Rizzi S, Meli E, Pascutto C, Paulli M, Lazzarino M: Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. Am J Hematol; 2010 Jan;85(1):46-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas.
  • We studied 160 Hepatitis C virus (HCV)-positive patients with NHL (59 indolent NHL, 101 aggressive).
  • At diagnosis, ALT value was above UNL in 67 patients.
  • One hundred and twenty patients received an anthracycline-based therapy, alkylators, 28 received chemotherapy plus rituximab.
  • Cytotoxic drugs dose was reduced in 63 patients.
  • Among 93 patients with normal ALT at presentation, 16 patients developed WHO grade II-III liver toxicity.
  • Among 67 patients with abnormal ALT, eight patients had a 3.5 times elevation during treatment.
  • Among 28 patients treated with rituximab and chemotherapy, five patients (18%) developed liver toxicity.
  • Thirty four patients (21%) did not complete treatment (eight for liver toxicity).
  • A significant proportion of patients with HCV+ NHL develop liver toxicity often leading to interruption of treatment.
  • HCV+ lymphomas represent a distinct clinical subset of NHL that deserves specific clinical approach to limit liver toxicity and ameliorate survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cytotoxins / adverse effects. Drug-Induced Liver Injury / virology. Hepatitis C, Chronic / complications. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / drug therapy

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19957347.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents, Alkylating; 0 / Biological Factors; 0 / Cytotoxins; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


81. Xicoy B, Ribera JM, Vaquero M, Grau J, Millá F, Feliu E: AA-type amyloid tumor as an unsuspected cause of residual mass in a patient with large B-cell non-Hodgkin's lymphoma. Leuk Lymphoma; 2002 Mar;43(3):681-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AA-type amyloid tumor as an unsuspected cause of residual mass in a patient with large B-cell non-Hodgkin's lymphoma.
  • Amyloidosis is a rare complication of non-Hodgkin's lymphoma (NHL).
  • AL amyloid deposits are usually localized in areas adjacent to the lymphoma, despite the presence of circulating light chains.
  • However, AA-type amyloidosis is extremely unfrequent as a residual mass in patients with NHL.
  • We report a case with diffuse large B-cell non-Hodgkin's lymphoma in which a residual tumoral mass corresponding to AA-type amyloidosis was found.
  • [MeSH-major] Amyloidosis / etiology. Lymphoma, Large B-Cell, Diffuse / complications
  • [MeSH-minor] Abdominal Neoplasms / etiology. Abdominal Neoplasms / pathology. Female. Humans. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / drug therapy. Middle Aged

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12002783.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


82. Annemans L, Moeremans K, Lamotte M, Garcia Conde J, van den Berg H, Myint H, Pieters R, Uyttebroeck A: Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer; 2003 Apr;11(4):249-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.
  • GOALS: Hyperuricaemia (HU) and tumour lysis syndrome (TLS) are complications of acute myeloid/lymphoid leukaemia (AML/ALL) and non-Hodgkin lymphoma (NHL) leading to increased morbidity and mortality.
  • Life expectancy at the time of diagnosis was based on published survival rates and age at diagnosis.
  • Reductions of HU/TLS following treatment with rasburicase were based on clinical trial data.
  • In adults, prevention is more cost-effective in NHL and ALL (maximum ICER of Eur 41383 and Eur 32126 per LYS).
  • Treatment of established HU/TLS with rasburicase is cost-saving in children and highly cost-effective in adults.
  • CONCLUSIONS: In conclusion, rasburicase, in addition to the demonstrated clinical benefit, is an economically attractive new option in the treatment of HU, both in adults and children.
  • In prevention the drug has an attractive economic profile in children, and is cost-effective in adults with ALL and NHL.
  • [MeSH-major] Hematologic Neoplasms / drug therapy. Hyperuricemia / drug therapy. Tumor Lysis Syndrome / drug therapy. Urate Oxidase / economics. Urate Oxidase / therapeutic use
  • [MeSH-minor] Adult. Child. Child, Preschool. Cost of Illness. Cost-Benefit Analysis. Drug Costs / statistics & numerical data. Europe / epidemiology. Humans. Incidence. Leukemia / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Middle Aged. Outcome and Process Assessment (Health Care). Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Nephrol. 1995 Apr;9(2):206-12 [7794722.001]
  • [Cites] Eur J Cancer. 2001 Apr;37(6):703-10 [11311644.001]
  • [Cites] JAMA. 1996 Nov 6;276(17):1409-15 [8892716.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):697-704 [11157020.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1505-9 [11587206.001]
  • [Cites] Am J Kidney Dis. 1999 Nov;34(5):E20 [10561160.001]
  • [Cites] Neth J Med. 2000 Apr;56(4):147-52 [10727760.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] BMJ. 2000 Aug 19-26;321(7259):510 [11012253.001]
  • [Cites] Health Econ. 1994 Sep-Oct;3(5):333-45 [7827649.001]
  • [Cites] Leukemia. 1997 Nov;11(11):1813-6 [9369411.001]
  • [Cites] Ned Tijdschr Geneeskd. 2000 Dec 16;144(51):2442-4 [11151651.001]
  • [Cites] Klin Padiatr. 1998 Jul-Aug;210(4):279-84 [9743966.001]
  • [Cites] Blood. 2001 May 15;97(10):2998-3003 [11342423.001]
  • [Cites] Drugs Today (Barc). 1999 Feb;35(2):79-87 [12973411.001]
  • [Cites] Eur J Cancer. 2001 Apr;37(6):695-702 [11311643.001]
  • [Cites] Eur J Cancer. 2001 Apr;37(6):687-94 [11311642.001]
  • (PMID = 12673464.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.7.3.3 / Urate Oxidase; EC 1.7.3.3. / rasburicase
  •  go-up   go-down


83. Landgren O, Pfeiffer RM, Stewart L, Gridley G, Mellemkjaer L, Hemminki K, Goldin LR, Travis LB: Risk of second malignant neoplasms among lymphoma patients with a family history of cancer. Int J Cancer; 2007 Mar 1;120(5):1099-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of second malignant neoplasms among lymphoma patients with a family history of cancer.
  • Radiotherapy and chemotherapy are known risk factors for second cancers after lymphoma.
  • We assessed risk of second cancers associated with family history of any cancer in 41,181 patients with Hodgkin lymphoma (HL) (n = 7,476), non-Hodgkin lymphoma (NHL) (n = 25,941), or chronic lymphocytic leukemia (CLL) (n = 7,764), using a large population-based database.
  • Family history of cancer was based on a diagnosis of any cancer in 110,862 first-degree relatives.
  • For NHL patients with positive (vs. negative) family history of cancer, we observed non-significantly increased risk of non-melanoma skin cancer (RR = 1.94, 95% CI: 0.86-4.38) and lung cancer (RR = 1.99, 95% CI: 0.73-5.39).
  • [MeSH-major] Hodgkin Disease / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Neoplasms, Second Primary / epidemiology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 17131330.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


84. Wang S, Jiang Y, Wu W, Yang D, Fang Q, Lin X, Li C: [Clinical analysis of primary head and neck non-Hodgkin's ]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Dec;16(12):676-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of primary head and neck non-Hodgkin's ].
  • OBJECTIVE: To research the clinical features of primary head and neck non-Hodgkin's lymphoms (NHL).
  • METHOD: 62 patients with primary head and neck NHL were analyzed in the positions of focuses, clinical aspects, diagnosis and treatment.
  • RESULT: Tonsilla palatina(25.8%), cervical lymphonodi (19.4%), nasal cavity and nasal sinuses(12.9%) were the common place of the origin of NHL which had various clinical manifestations.
  • High-grade malignant lymphomas represented 75.8% of these cases whose I E stage and II E stage were 38.7% and 24.2% respectively.
  • CONCLUSION: Head and neck NHL is generally high degree malignancy.
  • Accurate surgical biopsy linking immunohistochemical test will be advantageous to make a definite diagnosis.
  • Combining Chemotherapy and radiotherapy or operation should be put into practice to improve prognosis.
  • [MeSH-major] Head and Neck Neoplasms. Lymphoma, Non-Hodgkin

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12669443.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


85. Gerlier L, Lamotte M, Awada A, Bosly A, Bries G, Cocquyt V, Focan C, Henry S, Lalami Y, Machiels JP, Mebis J, Straetmans N, Verhoeven D, Somers L: The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma. BMC Cancer; 2010;10:642
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.
  • BACKGROUND: The use of chemotherapy regimens with moderate or high risk of febrile neutropenia (defined as having a FN incidence of 10% or more) and the respective incidence and clinical management of FN in breast cancer and NHL has not been studied in Belgium.
  • METHODS: Nine oncologists and six hematologists from different Belgian general hospitals and university centers were surveyed to collect expert opinion and real-life data (year 2007) on the use of chemotherapy regimens with moderate or high risk of febrile neutropenia and the clinical management of FN in patients aged <65 years with breast cancer or NHL.
  • In NHL patients (n = 39), R-CHOP-21 (33%) and R-ACVBP-14 (15%) were mainly used.
  • Overall, 30% of chemotherapy cycles observed in breast cancer patients were protected by PP/SP.
  • In 10 NHL patients receiving PP, 2 (20%) developed FN, whereas 13 (45%) of the 29 patients without PP developed FN and 3 (10%) PSN.
  • Overall, 55% of chemotherapy cycles observed in NHL patients were protected by PP/SP.
  • Impaired chemotherapy delivery (timing and/or dose) was reported in 40% (breast cancer) and 38% (NHL) of patients developing FN.
  • CONCLUSIONS: Despite the studied chemotherapy regimens being known to be associated with a moderate or high risk of FN, upfront G-CSF prophylaxis was rarely used.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Breast Neoplasms / drug therapy. Fever / chemically induced. Lymphoma, Non-Hodgkin / drug therapy. Neutropenia / chemically induced
  • [MeSH-minor] Academic Medical Centers. Adult. Aged. Belgium / epidemiology. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Guideline Adherence. Health Care Surveys. Hospitalization. Hospitals, General. Humans. Incidence. Male. Middle Aged. Practice Guidelines as Topic. Practice Patterns, Physicians'. Retrospective Studies. Time Factors. Treatment Outcome. Young Adult


86. Giné E, Gutiérrez-García G, López-Guillermo A: Current immunochemotherapy strategies in follicular lymphoma. Adv Ther; 2010 Oct;27(10):704-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current immunochemotherapy strategies in follicular lymphoma.
  • Nowadays, there is no consensus about the best treatment for patients with follicular lymphoma (FL) in differing situations.
  • In frontline treatment, a watchful waiting policy remains a good option if the patient has no risk criteria; the role of rituximab is under investigation in this setting.
  • In patients needing therapy, immunotherapy or immunochemotherapy are the best options; although it has not been established which chemotherapy, including cyclophosphamide, vincristine, and prednisone (CVP); cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP); fludarabine, or bendamustine combinations, is the best partner for rituximab.
  • Following frontline treatment, recent and still unpublished data strongly suggest a role for maintenance with rituximab, instead of observation only.
  • The role of maintenance after induction is well established, although comparative studies with autologous stem-cell transplantation (ASCT) or other combinations are warranted.
  • Other monoclonal antibodies, as well as vaccines and other immunotherapies, are currently under investigation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunotherapy / methods. Lymphoma, Follicular / therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived / administration & dosage. Bendamustine Hydrochloride. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Humans. Nitrogen Mustard Compounds / administration & dosage. Prednisone / administration & dosage. Radioimmunotherapy. Rituximab. Stem Cell Transplantation. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. Bendamustine .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20820973.001).
  • [ISSN] 1865-8652
  • [Journal-full-title] Advances in therapy
  • [ISO-abbreviation] Adv Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Nitrogen Mustard Compounds; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 981Y8SX18M / Bendamustine Hydrochloride; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone; CHOP protocol, modified; COP protocol 2
  •  go-up   go-down


87. Kim MK, Kim S, Lee SS, Sym SJ, Lee DH, Kim SW, Jang S, Park CJ, Chi HS, Huh J, Suh C: Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: a comparison with ESHAP. Transfusion; 2007 Aug;47(8):1447-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: a comparison with ESHAP.
  • BACKGROUND: It has previously been shown that ESHAP was an effective mobilization regimen for patients with pretreated lymphoma.
  • To extend these observations, the efficacy and feasibility of rituximab plus ESHAP regimen in CD20+ B-cell NHL were assessed.
  • RESULTS: The two treatment groups were well matched in patient characteristics.
  • Nineteen (95%) patients achieved optimal peripheral blood hematopoietic progenitor cell (PBPC) collection, defined as at least 5 x 10(6) CD34+ cells per kg.
  • Sixteen patients in the R-ESHAP group (73%) underwent autologous peripheral blood progenitor cell transplantation (APBPCT).
  • The median time to absolute neutrophil count at least 0.5 x 10(9) per L was 10 days (range, 8-17 days), and the median time to a platelet count of at least 20 x 10(9) per L was 12 days (range, 7-27 days).
  • CONCLUSION: Addition of rituximab to ESHAP chemotherapy did not have any adverse effects on PBPC mobilization.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Mobilization. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Methylprednisolone / administration & dosage. Middle Aged. Peripheral Blood Stem Cell Transplantation. Rituximab. Transplantation, Homologous

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17655589.001).
  • [ISSN] 0041-1132
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


88. Rice SC, Vacek PM, Homans AH, Kendall H, Rivers J, Messier T, Finette BA: Comparative analysis of HPRT mutant frequency in children with cancer. Environ Mol Mutagen; 2003;42(1):44-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The link between exposure to environmental mutagens and the development of cancer is well established.
  • Yet there is a paucity of data on the relationship between gene-environment interactions and the mechanisms associated with the somatic mutational events involved with malignant transformation, especially in children.
  • To gain insight into somatic mutational mechanisms in children who develop cancer, we determined the background mutant frequency (Mf) in the hypoxanthine phosphoribosyl transferase (HPRT) reporter gene of peripheral blood lymphocytes from pediatric cancer patients at the time of diagnosis and prior to therapeutic intervention.
  • We studied 23 children with hematologic malignancies and 31 children with solid tumors prior to initial therapeutic intervention.
  • Children with solid tumors, specifically sarcomas, and Hodgkin's disease were significantly older and had elevated HPRT Mfs (6.1 x 10(-6) and 3.7 x 10(-6), respectively) at the time of diagnosis, compared to normal controls (2.3 x 10(-6)) and other pediatric tumor groups including children with acute lymphocytic leukemia and non-Hodgkin's lymphoma (ALL/NHL, 1.7 x 10(-6)), central nervous system tumors (CNS, 3.6 x 10(-6)), and neuroblastoma (1.9 x 10(-6)).
  • In addition, these data demonstrate the importance of correcting for the effect of age when comparing the frequency of somatic mutations in children and should provide baseline data for future longitudinal biomonitoring studies on the genetic effects of chemotherapy in children treated for cancer.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12874812.001).
  • [ISSN] 0893-6692
  • [Journal-full-title] Environmental and molecular mutagenesis
  • [ISO-abbreviation] Environ. Mol. Mutagen.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / 1F32ES058701ZRG4; United States / NCI NIH HHS / CA / 1K01CA77737; United States / NICHD NIH HHS / HD / 1K11HD01010; United States / NICHD NIH HHS / HD / 1R29HD35309-01A1
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; EC 2.4.2.8 / Hypoxanthine Phosphoribosyltransferase
  •  go-up   go-down


89. Menzel H, Müller A, Von Schilling C, Licht T, Peschel C, Keller U: Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: analysis of remission induction and stem cell mobilization. Leuk Lymphoma; 2008 Jul;49(7):1337-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: analysis of remission induction and stem cell mobilization.
  • Chemotherapy with ifosfamide, epirubicin and etoposide (IEV) is an effective treatment regimen for refractory/relapsed non-Hodgkin lymphoma (NHL).
  • Rituximab has been shown to improve response rates, progression-free survival and overall survival in B-cell NHL.
  • This study included 85 patients who were treated with IEV or rituximab-IEV (R-IEV) for refractory/relapsed B-cell NHL.
  • Fifty-five patients (64.7%) proceeded to high-dose therapy after IEV+/-rituximab.
  • The median survival time was 60.0 months (IEV) and 19.5 months (R-IEV), and has not been reached for patients who received high-dose therapy.
  • The addition of rituximab to IEV salvage chemotherapy increases the response rates in B-cell NHL without affecting stem cell mobilization, but overall survival for patients proceeding to high-dose chemotherapy is not improved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Mobilization. Lymphoma, B-Cell / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Epirubicin / administration & dosage. Etoposide / administration & dosage. Female. Fever / chemically induced. Hematopoietic Stem Cell Transplantation. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Remission Induction. Rituximab. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604723.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 3Z8479ZZ5X / Epirubicin; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


90. Bosly A, Lepage E, Coiffier B, Fillet G, Herbrecht R, Divine M, Dupriez B, Nouvel C, Deconninck E, Tilly H, Bordessoule D, Gaulard P, Gisselbrecht C, GELA: Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma. Hematol J; 2001;2(4):279-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.
  • INTRODUCTION: A prospective randomised study involving 810 elderly patients was conducted in an attempt to compare alternating chemotherapy with conventional first-line chemotherapy in aggressive non-Hodgkin's lymphoma in order to improve prognosis with an acceptable toxicity for elderly patients.
  • This regimen was an association of active drugs in NHL relapsing patients, alternating VIMMM with ACVBP for induction and alternation of VIM and ACVM in consolidation.
  • RESULTS: The complete response rate after induction was superior for conventional first-line therapy (58.5% vs 48%, P = 0.003) but at the end of treatment, the CR rate was not statistically different (52% vs 48%, P = 0.19).
  • Conventional chemotherapy had a better five-year event-free survival than alternating regimen (33% (95% CI: 30-36%) vs 28% (95% CI: 26-30%), P = 0.0289) but overall survival was not statistically different (40% (CI 95% 38-42%) vs 36% (CI 95% 34-38%), P = 0.068).
  • In this elderly high risk population, the toxicity was very high: 19% in arm A and 26% in arm B died during treatment.

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11920261.001).
  • [ISSN] 1466-4860
  • [Journal-full-title] The hematology journal : the official journal of the European Haematology Association
  • [ISO-abbreviation] Hematol. J.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; RSA8KO39WH / Vindesine; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


91. Kato H, Taji H, Ogura M, Kagami Y, Oki Y, Tsujimura A, Fuwa N, Kodaira T, Seto M, Yamamoto K, Morishima Y: Favorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem cell transplantation after rituximab-containing induction chemotherapy with in vivo purging in relapsed or refractory follicular lymphoma. Clin Lymphoma Myeloma; 2009 Dec;9(6):443-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem cell transplantation after rituximab-containing induction chemotherapy with in vivo purging in relapsed or refractory follicular lymphoma.
  • PURPOSE: In this study, we sought to evaluate the efficacy and toxicity of high-dose therapy followed by autologous peripheral blood stem cell transplantation (autoPBSCT) after rituximab-containing induction chemotherapy with in vivo purging for relapsed or refractory chemosensitive advanced-stage follicular lymphoma (FL).
  • PATIENTS AND METHODS: A rituximab-containing regimen was used as induction chemotherapy and as in vivo purging before PBSC collection.
  • RESULTS: A total of 18 patients with a median age of 45 years were enrolled.
  • The number of previous chemotherapy regimens was 2.
  • The principal nonhematologic toxicities were grade 3 febrile neutropenia and diarrhea.
  • One patient experienced pneumocystis pneumonia, 2 developed interstitial pneumonitis, and 1 experienced agammaglobulinemia, all of whom had complete improvement except for the patient having agammaglobulinemia.
  • Grade 4 toxicities were not observed, and there have been neither treatment-related mortality nor secondary malignancy to date.
  • CONCLUSION: Consolidation of high-dose melphalan and TBI followed by autoPBSCT with in vivo purging is feasible and effective for relapsed or refractory chemosensitive FL.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / therapy. Peripheral Blood Stem Cell Transplantation. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19951884.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; Q41OR9510P / Melphalan
  •  go-up   go-down


92. Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE: High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant; 2006 Jul;12(7):703-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
  • Allogeneic hematopoietic cell transplantation (HCT) has been shown to be curative in a group of patients with aggressive non-Hodgkin lymphoma (NHL).
  • A previous study has demonstrated equivalent outcomes with a conditioning regimen based on total body irradiation and another not based on total body irradiation with preparative therapy using cyclophosphamide, carmustine, and etoposide (CBV) in autologous HCT.
  • Patients were required to have relapsed or be at high risk for subsequent relapse of NHL.
  • Each subject had a median of 3 previous chemotherapy regimens.
  • Median follow-up time was 11.5 months (range, .4-126).
  • None of the 12 patients who developed chronic GVHD has disease recurrence.
  • Patients who had required >3 previous chemotherapy regimens before HCT had an increased probability of relapse.
  • CBV is an effective preparative regimen for patients with aggressive NHL who undergo allogeneic HCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Carmustine / administration & dosage. Cause of Death. Combined Modality Therapy / methods. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Female. Graft vs Host Disease / mortality. Histocompatibility Testing. Humans. Male. Middle Aged. Survival Analysis. Transplantation, Homologous / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785059.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; U68WG3173Y / Carmustine; CBV protocol
  •  go-up   go-down


93. Querellou S, Valette F, Bodet-Milin C, Oudoux A, Carlier T, Harousseau JL, Chatal JF, Couturier O: FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol; 2006 Nov;85(11):759-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
  • Early therapy response assessment with metabolic imaging is potentially useful to determine prognosis in aggressive lymphoma and, thus, can guide first-line therapy.
  • Forty-eight patients with aggressive lymphoma [24 Hodgkin's disease (HD); 24 non-Hodgkin's lymphoma (NHL)] underwent fluoro-deoxyglucose positron emission tomography (FDG-PET) before chemotherapy (PET1) and at mid-treatment (PET2).
  • Therapeutic response was evaluated using conventional methods at mid-treatment.
  • PET2 was negative in 38 patients (18 NHL-20 HD) and positive in 10 (6 NHL-4 HD).
  • Of the PET-negative patients, 61 and 65% achieved complete remission, and only 50 and 25% of PET-positive patients, respectively, for NHL and HD, achieved complete remission.
  • Significant associations were found between PET2 and EFS (p = 0.0006) and OS (p = 0.04) for NHL, and EFS (p < 0.0001) for HD (but not for OS, because no HD patient died).
  • FDG-PET at mid-treatment can predict the outcome of patients with aggressive lymphoma and should be a useful tool to modify an ineffective therapy.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Positron-Emission Tomography / methods. Predictive Value of Tests. Tomography, Emission-Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Remission Induction. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871391.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


94. Sehn LH, Donaldson J, Filewich A, Fitzgerald C, Gill KK, Runzer N, Searle B, Souliere S, Spinelli JJ, Sutherland J, Connors JM: Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood; 2007 May 15;109(10):4171-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting.
  • The increasing usage of rituximab in the management of non-Hodgkin lymphoma (NHL) has created huge logistical challenges with respect to the delivery of this time- and labor-intensive drug.
  • To address these challenges, we developed and tested the feasibility of a 90-minute infusion schedule for rituximab (20% of the dose administered in the first 30 minutes, remaining 80% administered over 60 minutes).
  • A safety analysis performed in 150 patients receiving rituximab with corticosteroid-containing chemotherapy and 56 patients receiving rituximab as maintenance therapy demonstrated that this schedule was well tolerated, with no grade 3 or 4 infusion reactions observed.
  • [MeSH-major] Adrenal Cortex Hormones / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Chemotherapy, Adjuvant. Feasibility Studies. Hospitals, Community. Humans. Infusion Pumps. Middle Aged. Rituximab. Time Factors


95. Koch P, Probst A, Berdel WE, Willich NA, Reinartz G, Brockmann J, Liersch R, del Valle F, Clasen H, Hirt C, Breitsprecher R, Schmits R, Freund M, Fietkau R, Ketterer P, Freitag EM, Hinkelbein M, Heinecke A, Parwaresch R, Tiemann M: Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol; 2005 Oct 1;23(28):7050-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96).
  • PURPOSE: In the prospective study 02/96 on primary GI lymphoma, we have collected data on histology, clinical features, and treatment results.
  • In particular, in stages I and II localized primary gastric lymphoma (PGL), our objectives were to reduce treatment intensity and to confirm our hypothesis from study 01/92, which maintained that an organ-preserving approach is not inferior to primary surgery.
  • PATIENTS AND METHODS: Patients receiving radiotherapy and/or chemotherapy were stratified for histologic grade, stage, and whether surgery had been carried out or not (as decided by each participating center).
  • Patients with aggressive PGL received six cycles of CHOP-14 (cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by involved-field radiotherapy (40 Gy).
  • Patients with indolent PGL (including patients experiencing treatment failure with antibiotic therapy for Helicobacter pylori) were treated with extended-field radiotherapy.
  • The irradiation dose was 30 Gy, followed by a boost of 10 Gy (the latter omitted after complete resection) to the tumor region.
  • Of these patients, 393 with localized PGL were treated with radiotherapy and/or chemotherapy only or additional surgery between December 1996 and December 2003.
  • CONCLUSION: In this nonrandomized study (02/96), we reproduced the previous results of study 01/92 showing no disadvantage for an organ-preserving treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma / drug therapy. Lymphoma / radiotherapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dose Fractionation. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prospective Studies. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Jun 10;24(17):2682; author reply 2682-3 [16763284.001]
  • (PMID = 16129843.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


96. Rossum MM, Verhaegen NT, Jonkman MF, Mackenzie MA, Koster A, Van Der Valk PG, Span LF: Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: case report with review of novel treatment modalities. Leuk Lymphoma; 2004 Nov;45(11):2327-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: case report with review of novel treatment modalities.
  • In this paper a patient with a non-Hodgkin's lymphoma (NHL) and paraneoplastic pemphigus (PNP) is described.
  • Patients with PNP show severe, progressive mucocutaneous disease with a high mortality rate, because of drug-induced infectious complications.
  • However, pulse therapy with high doses of prednisolone (or dexamethasone) in combination with other immunosuppressants induces variable and inconstant results.
  • Another interesting therapeutic option is rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B-lymphocytes.
  • Administration of rituximab for patients with PNP in combination with follicular NHL is not always successful regarding oral lesions as we report in this case.
  • PE leading to prompt depletion of autoreactive antibodies combined with immunosuppressants or synchronisation of PE with IVIg seems the best treatment modality for this refractory group, but the therapeutic value and appropriate timing of rituximab obviously deserve further evaluation in patients with low grade NHL and PNP.
  • [MeSH-major] Lymphoma, Follicular / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adrenal Cortex Hormones / pharmacology. Aged. Antibodies, Monoclonal / metabolism. Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / biosynthesis. Antineoplastic Agents / pharmacology. Antineoplastic Agents, Hormonal / pharmacology. Azathioprine / pharmacology. B-Lymphocytes / metabolism. Cyclophosphamide / pharmacology. Dexamethasone / pharmacology. Glucocorticoids / pharmacology. Humans. Immunoglobulins, Intravenous / pharmacology. Immunosuppressive Agents / pharmacology. Male. Paraneoplastic Syndromes / drug therapy. Pemphigus / drug therapy. Plasma Exchange. Prednisolone / pharmacology. Prognosis. Rituximab. Time Factors

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Pemphigus.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15512825.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Glucocorticoids; 0 / Immunoglobulins, Intravenous; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; MRK240IY2L / Azathioprine
  •  go-up   go-down


97. Sakata K, Fuwa N, Kodaira T, Aratani K, Ikeda H, Takagi M, Nishio M, Satoh M, Nakamura S, Satoh H, Hareyama M: Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification. Radiother Oncol; 2006 May;79(2):179-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification.
  • BACKGROUND AND PURPOSE: This study was conducted to analyze the influence of radiotherapy doses and chemotherapy doses and clinical parameters on in-field disease control in order to assess the optimal radiation doses for treatment of mature T/NK-cell lymphomas according to the newly proposed WHO classification.
  • PATIENTS AND METHODS: Subjects consisted of 62 patients with mature T/NK-cell lymphomas treated with radiotherapy at four Japanese institutions between 1983 and 2002.
  • We reevaluated all histopathological specimens of non-Hodgkin's lymphomas (NHL), using the WHO classification.
  • Radiation therapy was usually delivered to the involved field.
  • The majority of patients also received adriamycin-based chemotherapy such as CHOP, modified CHOP, or more intensive chemotherapy.
  • RESULTS: There were no significant differences in radiosensitivity among subtypes of mature T/NK-cell lymphomas, at least between extranodal NK/T-cell lymphomas, nasal type and peripheral T-cell lymphomas, unspecified.
  • There was a radiation dose-response in non-bulky mature T/NK-cell lymphomas, indicating that radiation doses of more than 52 Gy may be required to obtain in-field control.
  • However, it was difficult to obtain local control of bulky T-cell lymphomas, even with high doses of irradiation.
  • CONCLUSIONS: Mature T/NK-cell lymphomas were more radioresistant than B-cell lymphomas such as diffuse large B-cell lymphomas (DLBCL).
  • The chemotherapy including adriamycin did not improve the in-field control of mature T/NK-cell lymphomas.
  • These results were obtained by using non-randomized data and the significance of these results is limited by bias in data.
  • However, our results suggest that the treatment strategy which is usually used for DLBCL, that is, a combined modality of CHOP and around 40 Gy of radiotherapy, may not be sufficiently effective for mature T/NK-cell lymphomas.
  • [MeSH-major] Lymphoma, T-Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Survival Analysis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644044.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Ireland
  •  go-up   go-down


98. Mohammadianpanah M, Ahmadloo N, Mozaffari MA, Mosleh-Shirazi MA, Omidvari S, Mosalaei A: Primary localized stages I and II non-Hodgkin's lymphoma of the nasopharynx: a retrospective 17-year single institutional experience. Ann Hematol; 2009 May;88(5):441-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary localized stages I and II non-Hodgkin's lymphoma of the nasopharynx: a retrospective 17-year single institutional experience.
  • The aim of this retrospective study was to define the natural history, clinicopathological findings, prognostic factors, and treatment outcome of 43 patients with localized stages I and II primary non-Hodgkin's lymphoma (NHL) of the nasopharynx, followed up in a single institution over a 17-year period.
  • Forty-three (13 women and 30 men) consecutive patients with localized stages I (N = 12) and II (N = 31) primary nasopharyngeal NHL were treated in our institution between 1990 and 2007.
  • The pathologic reports were classified according to the International Working Formulation (N = 22) or Revised European-American Lymphoma classification (N = 21).
  • The vast majority of patients (88%) were managed with a sequential combination of chemotherapy and radiation therapy.
  • Chemotherapy mainly consisted of 4-8 (median 6) cycles of CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisolone).
  • Involved-field radiation therapy with a median dose of 44 Gy was delivered to the primary site and entire cervical lymph nodes.
  • The majority of the patients (70%) had high-grade histology.
  • B-cell types represented 67% of the cases, among which diffuse large B cell was the most common histological subtype.
  • Our limited data suggest that primary nasopharyngeal NHL tends to have aggressive histology and unfavorable clinical course with poor outcome, despite a considerably localized disease at the time of presentation and high frequency of complete initial response rates.
  • Combined modality therapy should be considered for the majority of patients with primary localized nasopharyngeal NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Pharyngeal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Nasopharynx. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18931844.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


99. Engin H, Türker A, Abali H, Uner A, Günalp S: Successful treatment of primary non-Hodgkin's lymphoma of the vagina with chemotherapy. Arch Gynecol Obstet; 2004 Mar;269(3):208-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of primary non-Hodgkin's lymphoma of the vagina with chemotherapy.
  • INTRODUCTION: The vagina as a primary site of malignant lymphoma in woman is extremely rare.
  • CASE REPORT: We report here a 30-year-old patient with a primary vaginal non-Hodgkin's lymphoma stage IEA, follicular large cell of B lineage, with an excellent response to cytotoxic chemotherapy (CHOP) and event-free survival of 28 months.
  • CONCLUSION: Primary involvement of the vagina can be successfully treated by pelvic irradiation, but in young women chemotherapy should be considered to preserve fertility, as well as quality of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / drug therapy. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Female. Humans. Prednisone / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12904985.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


100. Grillo-López AJ: Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther; 2002 Oct;2(5):485-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma.
  • Immunotoxins, chemotherapy conjugates and radioimmunotherapies have been evaluated.
  • Zevalin, the first conjugated antibody for the treatment of non-hodgkin's lymphoma (NHL) (and the first radioimmunotherapeutic for cancer) was approved by the US FDA on 19 February 2002 (approval is pending in the EEC).
  • Several studies have been conducted including a randomized Phase III trial where it showed superiority to rituximab in overall response rate and in complete response rate.
  • The current indications are: low-grade or follicular lymphoma refractory to rituximab, and relapsed or refractory, low-grade, follicular or transformed lymphoma.
  • Additional studies have been initiated to further define the role of this new therapy in the treatment of patients with B-cell non-hodgkin's lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal / therapeutic use. Lymphoma / immunology. Lymphoma / therapy
  • [MeSH-minor] Clinical Trials as Topic. Combined Modality Therapy. Guidelines as Topic. United States. United States Food and Drug Administration

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12382517.001).
  • [ISSN] 1473-7140
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / ibritumomab tiuxetan
  • [Number-of-references] 30
  •  go-up   go-down






Advertisement